Skip to main content
Journal of Clinical & Translational Endocrinology logoLink to Journal of Clinical & Translational Endocrinology
. 2021 Nov 6;26:100274. doi: 10.1016/j.jcte.2021.100274

Amino acid sequence homology between thyroid autoantigens and central nervous system proteins: Implications for the steroid-responsive encephalopathy associated with autoimmune thyroiditis

Salvatore Benvenga a,b,c, Alessandro Antonelli d, Poupak Fallahi d, Carmen Bonanno e, Carmelo Rodolico e, Fabrizio Guarneri f,
PMCID: PMC8609095  PMID: 34849350

Highlights

  • Alpha-enolase, aldehyde reductase-I and dimethylargininase-I are SREAT autoantigens.

  • Molecular mimicry between thyroid and CNS autoantigens is hypothesized in SREAT.

  • Homology with TSH-R, Tg and TPO exists for 6, 27 and 47 of 46,809 CNS-proteins.

  • The above homologies are often in epitope-containing parts of thyroid autoantigens.

  • Most of the above proteins are expressed in CNS regions which are altered in SREAT.

Abbreviations: AChR, acetylcholine receptors; AD, Alzheimer disease; AKRIAI, aldehyde reductase-I; ALS, amyotrophic lateral sclerosis; AT, autoimmune thyroiditis; BBB, blood-brain barrier; BLAST, Basic Local Alignment Search Tool; CCP, complement control protein; DDAHI, dimethylargininase-I; EGF, epidermal growth factor; GD, Graves' disease; GPCR, G protein-coupled receptors; HE, Hashimoto’s encephalopathy; HT, Hashimoto’s thyroiditis; LRR, leucine-rich repeats; MG, myasthenia gravis; MuSK, muscular tyrosin kinase receptors; NMJ, neuromuscular junction; SREAT, steroid-responsive encephalopathy associated with autoimmune thyroiditis; TAb, anti-thyroid antibodies

Keywords: Graves’ disease, Hashimoto’s encephalopathy, Thyroglobulin, Thyroperoxidase, Thyrotropin receptors, Bioinformatics

Abstract

A few patients with Hashimoto’s thyroiditis or Graves’ disease develop a multiform syndrome of the central nervous system (CNS) termed Hashimoto’s encephalopathy or steroid-responsive encephalopathy associated with autoimmune thyroid disease (HE/SREAT). They have high levels of thyroid autoantibodies (TgAb, TPOAb and/or TSH-R-Ab) in blood and cerebrospinal fluid. Autoantibodies against alpha-enolase, aldehyde reductase-I (AKRIA) and/or dimethylargininase-I (DDAHI), proteins expressed in the CNS among other tissues, were detected in the blood and, when searched, in the cerebrospinal fluid of HE/SREAT patients. Recently, we reported that alpha-enolase, AKRIA and DDAHI share local sequence homology with each of the three autoantigens (TgAb, TPOAb, TSH-R-Ab), often in epitope-containing segments of the thyroid autoantigens. We hypothesized that there might be additional CNS-expressed proteins homologous to thyroid autoantigens, possibly overlapping known epitopes of the thyroid autoantigens. We used bioinformatic methods to address this hypothesis.

Six, 27 and 47 of 46,809 CNS-expressed proteins share homology with TSH-R, Tg and TPO, respectively. The homologous regions often contain epitopes, and some match regions of thyroid autoantigens which have homology with alpha-enolase, AKRIA and/or DDAHI. Several of the aforementioned proteins are present in CNS areas that show abnormalities at neuroimaging in HE/SREAT patients. Furthermore, autoantibodies against some of the said six, 27 and 47 proteins were reported to be associated with a number of autoimmune diseases.

Not only we validated our hypothesis, but we think that such a variety of potential CNS targets for thyroid Ab against epitopes contained in regions that have local homology with CNS proteins may explain the polymorphic phenotypes of HE/SREAT. Only when elevated amounts of these Ab are synthesized and trespass the blood-brain barrier, HE/SREAT appears. This might explain why HE/SREAT is so relatively rare.

Introduction

Hashimoto’s encephalopathy (HE) was initially described in 1966 in association with Hashimoto’s thyroiditis (HT) [1], and later found to be associated, although less frequently, with the other autoimmune thyroiditis (AT): Graves' disease (GD). Because, regardless of the HT or GD association, encephalopathy is very sensitive to corticosteroid therapy, another denomination is steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT). SREAT represents a rare complication of autoimmune thyroiditis [2] and may precede it even by years, similar to thyroid eye disease in patients with Graves disease [3], [4]. SREAT patients have abnormal electroencephalography and increased concentration of proteins/immunoglobulins G (IgG) in the cerebrospinal fluid, which can be observed in 90% and 80% of patients, respectively, but these findings are not specific of the disease [5]. Serum anti-thyroid antibodies (TAb) are typically elevated in SREAT patients, but their levels do not correlate with either severity or any specific clinical presentation.

Between 2002 and 2008, three autoantigens shared by the central nervous system (CNS) and the thyroid, and targeted by autoantibodies specifically present in SREAT patients, were identified: alpha-enolase, dimethylargininase-I (DDAHI) and aldehyde reductase-I (AKRIAI) [6], [7], [8]. This discovery led to the idea that autoimmunity against autoantigens common to CNS and thyroid could be one of the pathogenetic mechanisms of SREAT, in addition to the action of antithyroid autoantibodies on Tg, TPO and TSH-R expressed in the central nervous system [9].

In 2003, a paper described one patient with HE and reviewed the HE literature (85 patients who met their inclusion criteria out of “105 patients with brain dysfunction associated with possible Hashimoto thyroiditis”) [10]. This paper reported that pathologic findings were available for only three HE patients (one based on necropsy and two based on brain biopsy) [10]. In one patient, autopsy revealed lymphocytic infiltration in the brainstem (including its veins and venules), leptomeninx of the cortex, and cerebellum [11]. In the other two patients, biopsy revealed lymphocytic infiltration of the walls of many small arterioles and venules [12], and perivascular cuffs of lymphocytic cells [10]. Quite interestingly, Chong et al. [10] wrote that it could not be excluded that the high serum levels of TAb found in HE patients were originated by reaction to proteins (viral, bacterial, or toxic) causing brain damage or brain antigens released after injury, but there were no known proteins in the above categories with structural similarity to thyroid autoantigens.

For sake of completeness, we should note that Chong et al. [10] missed three patients. One was a French patient [13], in whom postmortem neuropathology demonstrated nonspecifically activated microglia. The second was a Japanese patient [14], in whom autopsy revealed no evidence of CNS vasculitis or other brain abnormalities. The third was an American patient with a questionable 7-mm area of the left medial frontal cortex at MRI [15]. Biopsy revealed moderate gliosis, some perivascular lymphoid cells and macrophages, scattered microglia in the parenchyma, but not vasculitis or microglial nodules [15].

In subsequent years, postmortem examination in HE patients demonstrated “mild perivascular lymphocytic infiltration throughout the brain and leptomeninges plus diffuse gliosis of gray matter in the cortex, basal ganglia, thalami, hippocampi, and, to a lesser extent, the parenchymal white matter[16]. Biopsy of other HE patients revealed: [i] “patchy myelin pallor, scant perivascular chronic inflammation, mild gliosis, and microglial activation[17]; [ii] primary vasculitis of the CNS [18]; [iii]“diffuse gliosis and perivascular lymphocyte infiltration with CD3 + T-cell predominance, … with no signs of a brain tumor” in a patient with a tumor-like lesion of the left caudate nucleus, “suggesting cerebral vasculitis as an underlying etiology[19]; [iv] non-vasculitic autoimmune inflammatory meningoencephalitis [20]; [v] reactive gliosis, angiogenesis, swollen vascular endothelial cells, mild lymphocyte infiltration (almost exclusively T cells) around small vessels [21].

Molecular mimicry between thyroid autoantigens and other autoantigens was mentioned by several authors as a possible clinically relevant causal mechanism of extrathyroid manifestations of thyroid autoimmunity, including some neurological and pychiatric disorders [22], [23], [24].

Just very recently, we demonstrated that there is striking local homology between thyroid autoantigens and the three HE/SREAT-autoantigens [25]. Particularly, Tg was homologous to 10 regions of alpha-enolase, 8 regions of AKRIAI, and 5 regions of DDAHI. TPO was homologous to 6 regions of alpha-enolase, 7 regions of AKRIAI, and 3 regions of DDAHI. Finally, TSH-R was homologous to 4 regions of alpha-enolase, 5 regions of AKRIAI, and 2 regions of DDAHI. Importantly, in regard to alpha-enolase (the sole of the three HE/SREAT autoantigens for which epitopes have been characterized), a total of 5 regions homologous to Tg, one region homologous to TPO, and one region homologous to TSH-R fell within, or adjacent to, epitopes of the protein. From the opposite perspective, a total of 4 regions of Tg, 5 of TPO and 2 of TSH-R homologous to alpha-enolase contained epitopes. Epitopes in each of the three thyroid autoantigens were present also in their regions that were homologous to regions of AKRIAI and DDAHI [25]. In brief, we provided some indirect evidence that a number of regions of homologies were relevant for the autoimmunity associated with HE/SREAT.

We hypothesized that alpha-enolase, AKRIAI and DDAHI might be the classic “tip of the iceberg”, viz. we hypothesized that there could be more proteins expressed in the CNS, not necessarily in a CNS-restricted expression mode, which share homology with at least one of the three thyroid autoantigens. Applying the same bioinformatic approach used for alpha-enolase, AKRIAI and DDAHI, we searched for such homologies.

Material and methods

We used our standard procedure, as in previous bioinformatics papers [25], [26], [27], [28], [29], [30], [31]. We retrieved the amino acid sequence of the precursors of the three “classical” human thyroid autoantigens, i.e. TSH-R (accession number P16473), Tg (accession number NP_003226) and TPO (accession number AAA61217) from the Entrez Protein database (https://www.ncbi.nlm.nih.gov/protein). Next, we probed each of these three autoantigens for amino acid sequence homology with human proteins of the same database whose records contained the term “brain” or “central nervous system”. Proteins labeled as “incomplete” or “hypothetical” were excluded. We also excluded alpha-enolase, AKRIAI and DDAHI, since they were investigated in our previous paper [25]. The Protein BLAST (Basic Local Alignment Search Tool) software version 2.8.0+ [32] was used to perform the comparison. Analysis was made with the standard parameters of the program, and only results with E < 10 were considered. Finally, the records of the proteins identified were manually reviewed, to exclude those not expressed in the CNS (the presence of the terms “brain” and/or “central nervous system” in the record was sometimes incidental, not related to the actual localization of the protein).

As also done previously [25], [26], [27], [28], [29], [30], [31], we verified the immunological relevance of the homologies selected, checking for their possible overlap(s) with known epitopes of TSH-R, Tg and TPO [26], [27], [28], [29], [30], [31], [33], [34], [35], [36]. To strengthen the immunological relevance of the homologies that we found, we searched the literature for the presence of serum autoantibodies against each of the thyroid autoantigen-homologous proteins in autoimmune diseases, including thyroid autoimmune diseases. To this aim, we searched in the PubMed database using the search string “(autoanti* OR autoimm* OR autoreact*) AND” followed by the name of each protein, and manually revised the results to select only relevant original articles.

To quickly know (i) which areas of the CNS express each of the proteins that we found to be thyroid autoantigen-homologous, and (ii) whether the thyroid gland also expressed these proteins, we probed the Expression Atlas (https://www.ebi.ac.uk/gxa/home) [37].

Results

CNS-expressed proteins found to be homologous to thyroid autoantigens

Table 1, Table 2 and Table 3 list which of the 46,809 CNS-expressed proteins in our databank, were homologous to TSH-R, Tg and TPO, respectively. There were 46 proteins (∼0.1%), 27 (∼0.06%) and 47 proteins (∼0.1%) that shared homology with TSH-R, Tg and TPO, respectively. Table 1, Table 2, Table 3 illustrate the span of the homologous segments, the degree of amino acid identity and overall amino acid homology (namely, identity plus similarity).

Table 1.

Homologies between TSH-R and proteins from brain or central nervous system.

Protein [Entrez Protein GI accession number] Protein segment TSH-R segment Identity Overall homology* E value Coincidences with**
1 Leucine-rich repeat-containing G-protein coupled receptor 4 (LGR4) [157694513] 20–253 20–252 24% 39% 1.19 × 10−4 Eno D
177–815 52–692 24% 44% 6.95 × 10−45 Eno A D
2 Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) [4504379] 234–868 32–732 24% 42% 1.25 × 10−43 Eno A D
3 Relaxin receptor 2/Leucine-rich repeat-containing G-protein coupled receptor 8 (LGR8) [18677729] 115–708 29–695 22% 40% 7.82 × 10−29 Eno A D
4 Relaxin receptor 1/Leucine-rich repeat-containing G protein-coupled receptor 7 (LGR7) [359279868] 182–738 182–710 25% 44% 1.75 × 10−34 Eno A D
5 Chondroadherin [153251229] 24–219 28–250 21% 44% 0.013 Eno D
6 Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 2 precursor (LINGO2) [22749183] 26–205 22–254 25% 43% 0.028 Eno D
7 Somatostatin receptor type 2 [4557859] 24–322 395–688 23% 41% 1.14 × 10−9 Eno A
8 Neuropeptide Y receptor type 1 [4505445] 50–331 424–689 24% 41% 2.07 × 10−8 Eno A
9 Apelin receptor [4885057] 38–318 424–687 25% 42% 2.78 × 10−8 Eno A
10 Neuromedin-K receptor/Neurokinin B receptor/Tachykinin receptor 3 [7669548] 84–382 418–696 26% 43% 4.26 × 10−8 Eno A
11 Free fatty acid receptor 3 [4885329] 88–334 494–731 20% 41% 5.11 × 10−7 Eno A
12 Melanopsin/Opsin-4 [15150803] 73–386 417–710 22% 36% 1.60 × 10−6 Eno A
13 G-protein coupled estrogen receptor 1/Membrane estrogen receptor [4504091] 68–332 423–686 23% 41% 5.02 × 10−6 Eno A
14 Alpha-1A adrenergic receptor [111118992] 9–354 393–706 20% 38% 1.71 × 10−5 Eno A
15 Vasopressin V1a receptor [4502331] 64–358 427–688 21% 39% 3.46 × 10−5 Eno A
16 Probable G-protein coupled receptor 34 [4885319] 26–367 370–727 19% 40% 3.86 × 10−5 Eno A
17 G-protein coupled receptor 26 [23592220] 79–200 494–609 26% 47% 7.64 × 10−5 Eno A
18 Orexin 2 receptor [1285033761] 71–163 424–523 28% 50% 8.46 × 10−5
19 Oxytocin receptor [32307152] 56–357 431–711 23% 40% 1.28 × 10−4 Eno A
20 Orexin receptor type 1 [222080095] 63–169 431–546 28% 44% 4.14 × 10−4
21 Galanin receptor type 2 [4503905] 37–302 426–688 22% 39% 6.07 × 10−4 Eno A
22 GPER protein [52350636] 68–274 423–639 24% 42% 6.90 × 10−4 Eno A
23 N/OFQ opioid receptor [385252102] 135–401 424–686 22% 41% 0.002 Eno A
24 Type 2 angiotensin II receptor [23238240] 103–350 481–707 24% 41% 0.002 Eno A
25 Alpha-1B adrenergic receptor [4501959] 57–357 426–687 19% 37% 0.006 Eno A
26 Mu opioid receptor [119568090] 142–453 424–744 20% 39% 0.011 Eno A
27 Melanin-concentrating hormone receptor 1 [397487122] 119–393 424–691 22% 40% 0.013 Eno A
28 Bombesin receptor subtype-3 [4502455] 60–339 427–687 19% 40% 0.023 Eno A
29 Neuropeptide Y receptor type 5 [5453796] 5–93 381–466 27% 50% 0.029 A
30 C3a anaphylatoxin chemotactic receptor [4757888] 331–444 576–687 22% 44% 0.151 A
31 Substance-P receptor/Tachykinin receptor 1 [4507343] 54–163 436–554 25% 41% 0.365
32 Proteinase-activated receptor 2 [34577052] 77–352 416–686 21% 39% 0.394 Eno A
33 Trace amine-associated receptor 6 (TaR-6) [28173558] 35–135 417–524 30% 53% 0.463
34 Urotensin-2 receptor/G-protein coupled receptor 14 [9506745] 115–323 487–686 23% 42% 0.515 Eno A
35 Nociceptin receptor [974065167] 132–322 508–686 25% 44% 0.779 Eno A
36 G-protein coupled receptor 24 [56554976] 149–267 584–691 24% 47% 0.812 A
37 C–C chemokine receptor type 7/Epstein-Barr virus-induced G-protein coupled receptor 1/MIP-3 beta receptor [4502641] 320–374 672–725 29% 49% 0.941
38 Olfactory receptor 2A14 [48717236] 96–164 494–562 30% 47% 1.001
39 Vasopressin V2 receptor [4557345] 267–326 620–679 30% 45% 1.119 A
40 Neuropeptide S receptor [46395496] 54–336 419–684 21% 42% 1.139 Eno A
41 Trace amine-associated receptor 8 (TaR-8) [16751917] 40–100 423–483 38% 60% 1.342
42 Neuropeptides B/W receptor type 2 [30581164] 58–326 427–688 24% 41% 2.476 Eno A
43 Olfactory receptor 2 J3 [185134902] 39–156 426–550 24% 44% 2.929
44 G protein-coupled receptor [953233] 299–318 670–689 55% 75% 7.670
45 Oxoglutarate (alpha-ketoglutarate) receptor 1 [52426789] 18–313 402–689 23% 38% 7.822 Eno A
46 5-hydroxytryptamine receptor 7 (5-HT7) [10880129] 111–389 445–683 20% 36% 8.232 Eno A

*Identical plus similar amino acids.

**Coincidences with segments of TSH-R homologous to known autoantigens of Hashimoto’s encephalopathy, i.e. alpha-enolase (Eno), AKRIAI (A) and DDAHI (D). Segments 149–161 and 560–575 of TSH-R are homologous to segments 40–52 and 284–299 of alpha-enolase, respectively. Segments 360–415, 396–402, 555–563 and 620–676 of TSH-R are homologous to segments 89–141, 258–264, 14–22, and 268–325 of AKRIAI, respectively. Segments 141–148 and 263–292 of TSH-R are homologous to segments 242–249 and 258–283 of DDAHI, respectively [25].

Table 2.

Homologies between thyroglobulin (Tg) and proteins from brain or central nervous system.

Protein [Entrez Protein GI accession number] Protein segment Tgs
egment
Identity Overall homology* E value Coincidences with**
1 Nidogen-1/Entactin [115298674] 847–919 660–726 35% 52% 1.23 × 10−5
849–917 96–161 39% 50% 1.61 × 10−5
859–922 1015–1076 43% 58% 8.51 × 10−7
867–925 1159–1216 45% 53% 4.60 × 10−4 Eno
874–919 315–358 45% 58% 0.002
880–919 882–921 35% 52% 0.281
2 Testican-1/Protein SPOCK [4759164] 281–368 972–1062 29% 46% 6.03 × 10−5
312–385 298–367 37% 52% 2.42 × 10−5 Eno
313–372 96–155 35% 51% 0.001
333–372 616–653 50% 67% 7.80 × 10−5
333–376 48–92 40% 62% 0.001
3 Testican-2/SPARC/osteonectin, CWCV, and Kazal-like domains proteoglycan 2 (SPOCK2) [7662036] 312–374 33–89 39% 52% 3.23 × 10−4 A
325–376 1019–1073 36% 54% 0.017
327–377 1160–1211 47% 64% 6.91 × 10−5 Eno
332–376 615–658 47% 63% 2.19 × 10−4
333–374 116–157 45% 59% 1.94 × 10−4
333–374 315–355 50% 66% 5.24 × 10−5
4 SPARC-related modular calcium-binding protein 1/ Secreted modular calcium-binding protein 1 (SMOC-1) [11545873] 54–149 50–151 28% 40% 0.034
54–158 1106–1210 30% 39% 1.39 × 10−4 Eno A
95–149 34–83 41% 54% 2.69 × 10−4 A
114–294 1027–1212 28% 42% 1.03 × 10−9 Eno A
116–292 181–358 25% 39% 8.360 Eno
119–317 881–1110 26% 38% 1.73 × 10−6 A
227–272 34–73 30% 52% 6.927 A
227–340 96–212 26% 39% 0.221
239–295 609–661 40% 54% 0.031
5 Testican-3 [3581970] 300–384 17–95 31% 43% 2.80 × 10−4 Eno
311–373 652–717 30% 52% 0.029
317–376 96–155 38% 46% 9.63 × 10−4
318–372 999–1062 42% 51% 1.42 × 10−5
337–376 315–353 45% 57% 0.018
337–376 616–653 42% 62% 0.005
337–376 1165–1205 48% 60% 5.46 × 10−4 Eno
6 SPARC-related modular calcium-binding protein 2/ Secreted modular calcium-binding protein 2 (SMOC-2) [262050673] 91–154 598–659 34% 56% 1.05 × 10−5
105–153 311–358 36% 51% 0.043
109–156 116–163 39% 52% 0.002
109–251 48–194 25% 40% 0.017
109–301 1027–1230 28% 43% 4.21 × 10−13 A
198–327 78–210 26% 40% 0.030
233–295 613–672 33% 50% 0.012
7 Insulin-like growth factor-binding protein 5 [10834982] 210–265 611–660 33% 51% 0.033
215–253 315–348 41% 56% 0.581
8 Signal peptide, CUB and EGF-like domain-containing protein 1 [120587029] 636–752 1427–1532 29% 36% 0.106
9 Ephrin type-B receptor 2 [822606583] 269–312 1473–1531 35% 44% 2.342
10 Ephrin type-B receptor 6 [294862532] 311–335 1470–1494 48% 60% 6.469
11 Ephrin type-A receptor 7 [568599847] 260–319 1457–1531 28% 42% 7.379
12 Acetylcholinesterase (Yt blood group) [219518823] 46–573 2211–2728 32% 50% 4.79 × 10−66 A D
13 Butyrylcholinesterase [1073548962] 9–527 2204–2722 29% 47% 2.43 × 10−61 A D
14 Neuroligin-3 [262359974] 66–596 2225–2730 30% 46% 1.36 × 10−52 A D
15 Neuroligin-4, X-linked [24308209] 70–539 2225–2671 29% 48% 2.60 × 10−51 A D
16 Neuroligin-4, Y-linked [256222771] 70–539 2225–2671 29% 48% 2.98 × 10−51 A D
17 Neuroligin-1 [1478051093] 77–546 2225–2671 31% 48% 1.49 × 10−49 A D
18 Carboxylesterase 3 (CES3) [297747275] 38–550 2204–2724 31% 44% 3.73 × 10−49 A D
19 Cocaine esterase [1463570077] 35–526 2204–2722 29% 45% 2.57 × 10−47 A D
20 Carboxylesterase 5A [298231153] 83–580 2225–2730 28% 44% 1.93 × 10−42 A D
21 Neuroligin-2 [30840978] 66–550 2225–2671 28% 43% 7.69 × 10−42 A D
22 Brain carboxylesterase hBr3 [6009628] 21–549 2197–2720 28% 44% 2.70 × 10−40 A D
23 Liver carboxylesterase 1/Acyl-coenzyme A:cholesterol acyltransferase/Brain carboxylesterase hBr1/Cocaine carboxylesterase/Egasyn/Methylumbelliferyl-acetate deacetylase 1/Monocyte/macrophage serine esterase/Retinyl ester hydrolase/Serine esterase 1/Triacylglycerol hydrolase [68508965] 21–552 2197–2723 28% 43% 9.33 × 10−40 A D
24 KIAA1480 protein, partial [7959221] 36–470 2298–2730 28% 46% 8.41 × 10−39 A D
25 Carboxylesterase 4A [1419235141] 30–509 2203–2669 29% 44% 4.62 × 10−37 A D
26 Carboxylesterase 8 (CES8) [40555853] 34–390 2318–2669 28% 44% 5.22 × 10−24 A D
27 KIAA1366 protein, partial [7243113] 1–265 2409–2671 22% 39% 0.002 A D

*Identical plus similar amino acids.

**Coincidences with segments of Tg homologous to known autoantigens of Hashimoto’s encephalopathy, i.e. alpha-enolase (Eno), AKRIAI (A) and DDAHI (D). Segments 298–329, 1171–1186, 1315–1337 and 1368–1385 of Tg are homologous to segments 18–48, 208–223, 375–395 and 280–297 of alpha-enolase, respectively. Segments 31–90, 1086–1114, 1107–1129 and 2612–2668 of Tg are homologous to segments 178–227, 111–140, 6–26 and 86–124 of AKRIAI, respectively. Segments 1597–1612, 2277–2286 and 2605–2617 of Tg are homologous to segments 64–81, 218–227 and 230–242 of DDAHI, respectively [25].

Table 3.

Homologies between thyroid peroxidase (TPO) and proteins from brain or central nervous system.

Protein [Entrez Protein GI accession number] Protein segment TPO segment Identity Overall homology* E value Coincidences with**
1 Peroxidasin homolog/Melanoma-associated antigen MG50/Vascular peroxidase 1 [109150416] 604–1314 8–734 41% 58% 1.89 × 10−175 Eno A D
2 Peroxidasin-like protein [633365073] 516–1201 40–734 38% 55% 5.01 × 10−150 Eno A D
3 Prostaglandin G/H synthase 2/Cyclooxygenase-2 [4506265] 208–340 318–459 28% 43% 1.50 × 10−8 A
4 Prostaglandin G/H synthase 1/Cyclooxygenase-1 [18104967] 227–518 324–650 22% 40% 1.35 × 10−5 Eno A D
5 Fibrillin-1/Asprosin/Epididymis secretory sperm binding protein [311033452] 515–572 768–840 32% 47% 0.011
570–613 794–840 36% 55% 0.129
611–655 794–841 43% 56% 3.33 × 10−4
723–765 796–840 37% 55% 0.015
908–952 794–840 36% 51% 0.063
1024–1070 792–840 38% 48% 0.005
1068–1104 794–832 38% 51% 1.620
1174–1238 774–840 29% 46% 1.196
1216–1280 775–840 33% 52% 9.48 × 10−4
1344–1404 776–840 38% 55% 4.31 × 10−5
1392–1455 784–847 27% 50% 0.635
1645–1692 793–843 35% 45% 0.166
1888–1930 793–840 37% 50% 2.828
1928–1973 794–840 53% 63% 8.86 × 10−7
1973–2055 752–840 31% 47% 2.29 × 10−5
2129–2199 740–832 30% 45% 0.005
2244–2291 793–840 37% 52% 2.02 × 10−4
2289–2334 794–841 33% 47% 0.546
2413–2507 768–862 34% 46% 3.61 × 10−5
2522–2567 794–840 36% 46% 0.340
2575–2648 766–840 30% 47% 5.324
2646–2678 794–829 47% 58% 0.198
6 Adhesion G protein-coupled receptor E2/EGF-like module receptor 2/CD312 [23397681] 65–101 794–830 40% 59% 0.030
158–191 791–825 54% 62% 1.82 × 10−4
209–240 793–825 45% 63% 0.155
7 Protocadherin Fat 4 [165932370] 3799–3897 746–838 34% 41% 3.33 × 10−4
8 Low-density lipoprotein receptor-related protein 4 (LRP-4) [157384998] 359–433 747–838 33% 46% 4.08 × 10−4
9 Latent-transforming growth factor beta-binding protein 4 (LTBP4) [110347431] 355–397 794–839 36% 54% 0.431
585–636 794–847 38% 50% 0.506
627–671 794–840 42% 51% 1.506
750–794 794–840 44% 59% 0.064
872–920 790–840 43% 50% 0.023
1047–1091 794–840 51% 61% 5.63 × 10−4
1539–1604 764–825 37% 55% 1.419
10 Fibrillin-3 [56237021] 487–557 794–866 36% 46% 0.004
570–614 794–841 39% 54% 0.174
681–724 795–840 39% 56% 0.323
763–816 793–852 35% 46% 5.987
867–911 794–840 44% 53% 0.396
982–1028 792–840 42% 44% 0.874
1153–1196 794–840 38% 48% 1.322
1169–1238 770–840 35% 47% 0.074
1443–1487 794–841 41% 52% 0.992
1884–1930 794–841 43% 52% 0.041
1959–2012 786–841 35% 51% 0.217
2083–2148 795–862 35% 45% 0.196
2204–2236 793–825 50% 64% 1.605
2368–2468 762–862 31% 42% 0.001
2483–2528 794–840 41% 50% 5.275
2536–2601 766–831 39% 52% 0.078
2598–2640 786–829 47% 56% 4.494
11 Latent-transforming growth factor beta-binding protein 1 (LTBP-1) [290457687] 902–979 785–862 28% 42% 0.034
1074–1286 626–840 24% 36% 0.013 Eno
1200–1244 794–840 43% 56% 0.001
1436–1507 768–839 28% 45% 0.440
1621–1706 738–839 29% 36% 2.230
12 Seizure related 6-like protein 2 [608785583] 541–610 736–802 33% 45% 0.003
13 CUB and sushi domain-containing protein 1 [259013213] 1200–1282 739–805 29% 38% 0.968
2478–2555 727–797 34% 48% 0.003
14 C-type lectin domain family 14 member A/Epidermal growth factor receptor 5 (EGFR-5) [28269707] 256–290 808–842 51% 60% 0.004
15 fibrillin 1 variant, partial [62087260] 438–490 786–840 38% 54% 0.005
16 Multiple epidermal growth factor-like domains protein 6 [110347457] 247–324 745–838 34% 45% 0.008
17 Seizure 6-like protein/KIAA0927 protein [296179442] 392–449 741–795 34% 48% 0.009
18 Cadherin EGF LAG seven-pass G-type receptor 2/Cadherin family member 10/Flamingo homolog 3 [13325064] 1296–1351 807–862 40% 50% 0.011
19 Low-density lipoprotein receptor-related protein 2 (LRP-2) [126012573] 1388–1428 794–838 40% 51% 0.386
3136–3191 767–838 31% 44% 0.550
4000–4054 789–845 38% 49% 0.011
20 EGF-containing fibulin-like extracellular matrix protein 2 [14714634] 121–164 794–840 44% 48% 0.272
141–203 772–840 34% 50% 0.012
263–319 776–829 36% 50% 0.120
21 Nephronectin/Preosteoblast EGF-like repeat protein with MAM domain/EGFL6-like [75709198] 212–259 794–847 38% 61% 0.016
22 Complement component C1q receptor/CD93 [88758613] 326–369 766–825 38% 46% 5.378
383–427 794–840 45% 56% 0.016
410–468 767–839 34% 45% 0.367
23 Fibulin 5 [19743803] 113–161 768–831 35% 48% 0.019
24 Tolloid-like protein 1 [22547221] 567–614 789–838 42% 50% 0.020
25 EGF-containing fibulin-like extracellular matrix protein 1 [86788015] 204–254 786–840 38% 52% 0.023
26 Signal peptide, CUB and EGF-like domain-containing protein 1 [120587029] 64–117 786–840 29% 49% 1.882
270–323 786–840 42% 50% 0.023
360–407 794–844 33% 56% 3.772
27 Latent-transforming growth factor beta-binding protein 1 (LTBP1) [219518146] 576–665 785–881 26% 40% 0.032
28 KIAA1237 protein, partial [34327974] 912–944 796–831 47% 58% 0.040
29 Vitamin K-dependent protein S [192447438] 137–201 776–840 32% 50% 0.041
30 Protein HEG homolog 1 [153792110] 1025–1057 796–831 47% 58% 0.047
31 Low-density lipoprotein receptor-related protein 1B (LRP-1B) [93102379] 96–155 793–840 28% 41% 5.824
104–193 745–838 28% 45% 0.049
2909–2968 793–840 31% 50% 0.817
2966–3002 794–834 46% 63% 0.081
32 P-selectin (CD62P)/Granule membrane protein 140/Leukocyte-endothelial cell adhesion molecule 3/Platelet activation dependent granule-external membrane protein [215274139] 531–621 759–843 31% 47% 0.053
33 Fibulin-1 (FIBL-1) [215274249] 475–552 752–824 31% 46% 0.065
34 Fibulin 1 [18490682] 189–257 755–834 35% 45% 0.257
354–405 794–846 41% 47% 0.066
390–441 787–840 37% 51% 0.404
35 Protein kinase C-binding protein NELL2 [223029476] 461–500 794–834 43% 58% 0.067
36 NOTCH4 protein [187954607] 192–230 795–838 43% 50% 6.636
272–342 756–825 32% 46% 0.077
37 complement receptor type 2 [54792123] 398–467 731–795 33% 43% 2.909
935–970 764–798 50% 58% 0.103
38 dual oxidase 2 precursor variant, partial [62087600] 59–106 650–695 33% 60% 0.113
39 Nidogen-1/Entactin [115298674] 800–840 794–839 43% 50% 0.132
40 CSMD2 protein [62954774] 2404–2593 627–802 25% 38% 0.135 Eno
41 Cysteine-rich with EGF-like Domains 2 (CRELD2) beta [67511376] 202–266 767–839 35% 45% 0.135
42 Endosialin/CD248 [9966885] 283–356 755–844 26% 38% 0.203
43 Epidermal growth factor-like protein 7 [7705889] 137–185 796–847 40% 50% 0.208
44 Prolow-density lipoprotein receptor-related protein 1/ Alpha-2-macroglobulin receptor/Apolipoprotein E receptor/CD91 [126012562] 148–188 794–838 42% 53% 2.343
2941–3012 797–863 35% 43% 0.251
45 CUB and sushi domain-containing protein 3 [38045888] 2874–2939 741–806 34% 44% 0.260
46 Thrombospondin-3 [6005902] 367–397 793–823 41% 64% 0.268
47 Epidermal growth factor-like protein 6 [13124888] 93–135 795–841 42% 53% 1.360
217–252 794–830 43% 56% 0.270
48 Mutant p53 binding protein 1 variant, partial [62087822] 254–293 796–840 35% 53% 0.782

*Identical plus similar amino acids.

**Coincidences with segments of TPO homologous to known autoantigens of Hashimoto’s encephalopathy, i.e. alpha-enolase (Eno), AKRIAI (A) and DDAHI (D). Segments 603–627, 609–623, 637–659, 700–722, 710–721 of TPO are homologous to segments 261–281, 227–241, 211–233, 243–265, 346–357 of alpha-enolase, respectively. Segments 333–369, 410–456, 421–428 and 535–552 of TPO are homologous to segments 282–324, 22–72, 289–296 and 169–186 of AKRIAI, respectively. Segment 492–566 of TPO is homologous to segment 10–77 of DDAHI [25].

Making reference to Table 2 as an example for describing the other two Tables (Table 1 and Table 3), there are proteins with a single segment of homology each, such as butyrylcholinesterase (aa 9–527 matching aa 2204–2722 of Tg), and other proteins with multiple segments of homology (which are listed from the most N-terminal to the most C-terminal position). Examples of this multiplicity are the nine segments of SPARC-1/SMOC-1 that are homologous to Tg. Close inspection of these nine segments (Table 2) shows that they fall within the long region 54–340 of SPARC-1/SMOC-1, which matches a discontinuous and much longer region of Tg comprised between aa 34 and 1212. Indeed, two long stretches of Tg (aa 359–608 and 662–880) did not match any segment of aa 54–340 of SPARC-1/SMOC-1. The extent of amino acid identity with Tg segments ranges from 22% (KIAA1366 protein) to 50% (aa 333–372 of testican-1 and aa 333–374 of testican-2), and overall homology from 36% (aa 636–752 of signal peptide, CUB and EGF-like domain-containing protein 1) to 67% (aa 333–372 of testican-1). Of interest, the group of Tg segments homologous to CNS-expressed proteins (Table 2) and the group of Tg segments homologous to alpha-enolase, AKRIAI or DDAHI [25] showed several overlaps. In detail, Tg segments of the first group fully contained a Tg segment of the second group in 59 cases (with some multiple matches) and were fully contained in a Tg segment of the second group in 3 cases, while a partial overlap of more than 10 residues was observed in 10 cases.

This pattern of proteins having a single segment of homology (for instance, protocadherin Fat 4) or other proteins having multiple segments of homology (for instance, fibrillin-1 and fibrillin-3) applied to TPO (Table 3). Identity with TPO ranges from 22% (prostaglandin G/H synthase 1/cyclooxygenase-1) to 54% (aa 158–191 of Adhesion G protein-coupled receptor E2/EGF-like module receptor 2/CD312), and overall homology from 36% (aa 1621–1706 of LTBP-1) to 64% (thrombospondin-3 and aa 2204–2236 of fibrillin-3). TPO segments homologous to CNS-expressed proteins (Table 3) fully contained a Tg segment homologous to alpha-enolase, AKRIAI or DDAHI [25] in 36 cases (with many multiple matches), and two partial overlaps of more than 10 residues were also observed.

In the case of TSH-R (Table 1), with the only exception of LGR4, all proteins (which were cell receptors, except chondroadherin) had a single segment of homology with the thyroid autoantigen. Identity with TSH-R ranges from 19% (probable G-protein coupled receptor 34, alpha-1B adrenergic receptor and bombesin receptor subtype-3) to 55% (G protein-coupled receptor), and overall homology from 36% (Melanopsin/Opsin-4 and 5-hydroxytryptamine receptor 7) to 75 % (G protein-coupled receptor). TSH-R segments homologous to CNS-expressed proteins (Table 1) fully contained a Tg segment homologous to alpha-enolase, AKRIAI or DDAHI [25] in 122 cases (with many multiple matches), while the partial overlaps of more than 10 residues were five.

Topographic position of the homologous proteins with respect to domains and epitopic regions of each thyroid autoantigen

Fig. 1 provides illustrative examples for TSH-R, Tg and TPO (top, middle and bottom panel, respectively), with their epitopes highlighted.

Fig. 1.

Fig. 1

Illustrative examples of amino acid sequence homologies between CNS proteins and TSH-R, Tg and TPO (top, middle and bottom panel, respectively). Epitopes of the three thyroid autoantigens are underlined.

The position of sequence homology within given domains of the three thyroid autoantigens can be appreciated in Fig. 2, Fig. 3, Fig. 4. Of the 46 proteins homologous to TSH-R (Fig. 2), only the first 6 (LGR4, LGR5, relaxin receptor 1, relaxin receptor 2, chondroadherin and LINGO2) match the whole length of TSH-R, while the others match the serpentine domain, most frequently for its whole length. A few proteins match the C-terminus of the extracellular domain, and a few match the intracellular domain. With the single exception of G protein-coupled receptor and C–C chemokine receptor type 7 (whose homology with TSH-R starts at aa 670 and 672, respectively, of the thyroid autoantigen), all other 44 proteins matched TSH-R regions containing at least one epitope (Fig. 2).

Fig. 2.

Fig. 2

Homologies between CNS-expressed proteins and TSH-R. Segments in black represent single homologous sequences, segments in gray represent the cumulative span of multiple, overlapping homologous sequences of the same protein.

Fig. 3.

Fig. 3

Homologies between CNS-expressed proteins and Tg. Segments in black represent single homologous sequences, segments in gray represent the cumulative span of multiple, overlapping homologous sequences of the same protein.

Fig. 4.

Fig. 4

Homologies between CNS-expressed proteins and TPO. Segments in black represent single homologous sequences, segments in gray represent the cumulative span of multiple, overlapping homologous sequences of the same protein.

Concerning Tg (Fig. 3), of the 27 homologous proteins, 7 matched a long N-terminal region, 4 a very short central region, and the remaining 11 the acethylcolinesterase-like domain at the C-terminus of Tg. Noteworthy, all 27 proteins matched regions of Tg containing at least one epitope, including the short Tg segment 1470–1494 matched by Ephrin type-B receptor 6, since the aa sequence 1473–1526 of Tg is epitopic (Fig. 3).

Concerning TPO (Fig. 4), of the 48 homologous proteins, 2 (peroxidasin homolog, and peroxidasin-like protein) matched the long whole heme-peroxidase domain (residues 142–738) and the N-terminal segment ahead of it, 3 matched part of the heme-peroxidase domain (prostaglandin G/H synthase 1, prostaglandin G/H synthase 2, and dual oxidase 2 precursor variant), while the remaining 43 matched the complement control protein-like domain (CCP-like domain at residues 740–795) and/or the epidermal growth factor (EGF)-like domain (EGF-like domain, residues 796–846), with a few matching also the end of the heme-peroxidase and a few matching part of the transmembrane domain (residues 847–871). Noteworthy, one CNS-protein (nidogen-1/entactin), shared homology also with Tg. The segment 800–840 of nidogen-1/entactin was 43% identical and 50% homologous to the segment 794–839 of TPO (Table 3 and Fig. 4). On the other hand, 6 segments of nidogen-1/entactin spanning aa 847–925 were 35–45% identical and 50–58% homologous to six segments of Tg: 96–161, 315–358, 660–726, 882–921, 1015–1076 and 1159–1216 (Table 2 and Fig. 3). While the segment 794–839 of TPO, and 315–358, 660–726, 882–921 and 1015–1076 of Tg do not contain epitopes, the Tg segment 96–161 and 1159–1216 contain epitopes at aa 20–190, 1116–1168 and 1168–1269 (Fig. 3 and Fig. 4).

For 18 of the proteins shown in Table 3, all homologies were with segments of TPO which do not contain epitopes or had 6 or less amino acids of overlap with TPO epitopes. These proteins were, in alphabetical order: adhesion G protein-coupled receptor E2, C-type lectin domain family 14 member A, dual oxidase 2 precursor variant, EGF-containing fibulin-like extracellular matrix protein 1, EGF-containing fibulin-like extracellular matrix protein 2, EGF-like protein 6, EGF-like protein 7, fibrillin 1 variant, KIAA1237 protein, mutant p53 binding protein 1, nephronectin, nidogen-1, protein HEG homolog 1, protein kinase C-binding protein NELL2, signal peptide, CUB and EGF-like domain-containing protein 1, thrombospondin-3, tolloid-like protein 1, vitamin K-dependent protein S. For 16 other proteins, homologies included only segments belonging to IDR-B: this was the case of fibrillin-1, protocadherin Fat 4, low-density lipoprotein receptor-related protein 4, latent-transforming growth factor beta-binding protein 4, seizure related 6-like protein 2, CUB and sushi domain-containing protein 1, multiple epidermal growth factor-like domains protein 6, seizure 6-like protein, complement component C1q receptor, low-density lipoprotein receptor-related protein 1B, P-selectin, fibulin-1, NOTCH4 protein, complement receptor type 2, endosialin, CUB and sushi domain-containing protein 3.

The thyroid-autoantigen-homologous proteins are expressed in given areas of the CNS, and almost all of them are expressed in the thyroid

SupplementaryTables 1–3 summarize information from the Expression Atlas (https://www.ebi.ac.uk/gxa/home) [37] about the expression of the proteins homologous to TSH-R, Tg and TPO, respectively, in different areas of the CNS and in the thyroid.

The same Supplementary Tables also show, highlighted in gray, which areas of CNS expressing thyroid autoantigen-homologous proteins were found to show abnormalities at diagnostic neuroimaging in patients with HE/SREAT (references about these data are available upon request). Of these areas, those with the highest number of TSH-R-homologous proteins expressed were frontal lobe (n = 36), cerebral cortex (n = 34), frontal cortex and temporal lobe (n = 33 each); those with the highest number of Tg-homologous proteins expressed were frontal lobe and temporal lobe (n = 26 each) followed by brain, cerebral cortex and frontal cortex (n = 25 each); those with the highest number of TPO-homologous proteins expressed were brain (n = 47), temporal lobe (n = 45), cerebral cortex, frontal cortex and frontal lobe (n = 44 each).

For a few proteins homologous to TSH-R (free fatty acid receptor 3, trace amine-associated receptor 6, olfactory receptor 2A14, trace amine-associated receptor 8, olfactory receptor 2 J3), the Expression Atlas provides no details on which CNS areas express these proteins. Also for a few proteins, the same Atlas provides no details as to whether the thyroid gland expresses these proteins, or reports that their expression is below the cutoff value considered (Supplementary Tables 1–3). Supplementary Table 4 shows data reported in the Expression Atlas about the expression of the three currently known autoantigens of HE/SREAT in the thyroid and in the brain/CNS.

Autoantibodies against the thyroid-autoantigen-homologous CNS-expressed proteins have been detected in a number of autoimmune diseases

As explained under Materials and Methods, we probed the literature for articles on the presence of serum autoantibodies against each of the thyroid autoantigen-homologous proteins in autoimmune diseases, including thyroid autoimmune diseases, by performing a PubMed search with the string “(autoanti* OR autoimm* OR autoreact*) AND” followed by the name of each protein and manually selecting relevant original papers [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], [88], [89], [90], [91], [92], [93]. As summarized in Table 4, of the 46 CNS proteins homologous to TSH-R, 5 (11%; LGR4, chondroadherin, alpha-1A adrenergic receptor, Mu opioid receptor, and melanin-concentrating hormone receptor 1) were reported to stimulate autoAb, and in the following conditions: CNS demyelinating disease, autoimmune hepatitis, refractory hypertension, psychiatric disorders, chronic fatigue syndrome and vitiligo [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51]. Of the utmost interest are anti-LGR4 autoAbs, because they were detected also in patients with AIT [30]. Noteworthy is also information available on epitopes of melanin-concentrating hormone receptor 1 [27], with aa 85–98 and 254–260 being major autoantibody epitopes, aa 51–80 and 154–158 being minor autoantibody epitopes, and aa 254–260 being the target of function-blocking antibodies. Thus, the segment 119–393 of melanin-concentrating hormone receptor 1, which we found to be homologous to the segment 424–691 of TSH-R contains epitopes (aa 154–158 and 254–260), as does the homologous TSH-R segment (epitope at aa 441–661).

Table 4.

Involvement in autoimmune disorders, as resulting from a PubMed search, of the proteins that we found share local homology with thyrotropin receptor (TSH-R).

Protein No. of articles Citations Results
Leucine-rich repeat-containing G-protein coupled receptor 4 (LGR4) 1 Greer JM et al. 2017 [38] Patients with both CNS disease and AITD have elevated levels of T cells and antibodies to LGR4, which is expressed in brainstem and spinal cord
Chondroadherin 1 Mazzara S et al. 2015 [39] Autoantibodies to chondroadherin are present in autoimmune hepatitis patients and could be used as diagnostic/prognostic markers
Alpha-1A adrenergic receptor 2 Wenzel K et al. 2008 [40] Agonistic autoantibodies to alpha-1A adrenergic receptor are present in patients with hypertension and are a possible cause of hypertension.
Wenzel K et al. 2010 [41] In a rat model, autoantibodies to alpha-1A adrenergic receptor may contribute to cardiovascular damage.
Mu opioid receptor 5 Tanaka S et al. 2003 [42] Autoantibodies to mu opioid receptor were found in 13.1% of 122 psychiatric patients.
Tanaka S et al. 2003 [43] Autoantibodies to mu opioid receptor were found in 15.2% of 60 patients with chronic fatigue syndrome
Macé G et al. 2002 [44] Autoantibodies to mu opioid receptor are commonly expressed in healthy humans and may promote Fas-mediated apoptosis
Macé G et al. 1999 [45] Autoantibodies that bind the first and third extracellular loops of the mu opioid receptor mimic morphine-induced receptor activation
Macé G et al. 1999 [46] Some IgG autoantibodies to mu opioid receptor have a morphine-like activity
Melanin-concentrating hormone receptor 1 5 Kroon MW et al. 2013 [47] Autoantibodies to melanin-concentrating hormone receptor 1 are common in the sera of patients with vitiligo
Li Q et al. 2011 [48] Melanin-concentrating hormone receptor 1 is a well-known autoantigen in vitiligo
Gavalas NG et al. 2009 [49] In vitiligo patients, peptides 85–98 and 254–260 are major autoantibody epitopes of melanin-concentrating hormone receptor 1, peptides 51–80 and 154–158 are minor autoantibody epitopes, peptide 254–260 is the target of function-blocking antibodies.
Gottumukkala RV et al. 2003 [50] Several domains of melanin-concentrating hormone receptor 1 are recognized by autoantibodies from vitiligo patients.
Kemp et al. 2002 [51] Melanin-concentrating hormone receptor 1 is an autoantigen in vitiligo

Of the 46 TSH-R homologous proteins, 41 do not appear in the Table, because we retrieved no literature about their involvement in autoimmune disorders. These proteins are: Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), Relaxin receptor 2/Leucine-rich repeat-containing G-protein coupled receptor 8 (LGR8), Relaxin receptor 1/Leucine-rich repeat-containing G protein-coupled receptor 7 (LGR7), Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 2 (LINGO2), Somatostatin receptor type 2, Neuropeptide Y receptor type 1, Apelin receptor, Neuromedin-K receptor/Neurokinin B receptor/Tachykinin receptor 3, Free fatty acid receptor 3, Melanopsin/Opsin-4, G-protein coupled estrogen receptor 1/Membrane estrogen receptor, Vasopressin V1a receptor, Probable G-protein coupled receptor 34, G-protein coupled receptor 26, Orexin 2 receptor, Oxytocin receptor, Orexin receptor type 1, Galanin receptor type 2, GPER protein, N/OFQ opioid receptor, Type 2 angiotensin II receptor, Alpha-1B adrenergic receptor, Bombesin receptor subtype-3, Neuropeptide Y receptor type 5, C3a anaphylatoxin chemotactic receptor, Substance-P receptor/Tachykinin receptor 1, Proteinase-activated receptor 2, Trace amine-associated receptor 6 (TaR-6), Urotensin-2 receptor/G-protein coupled receptor 14, Nociceptin receptor, G-protein coupled receptor 24, C–C chemokine receptor type 7/Epstein-Barr virus-induced G-protein coupled receptor 1/MIP-3 beta receptor, Olfactory receptor 2A14, Vasopressin V2 receptor, Neuropeptide S receptor, Trace amine-associated receptor 8 (TaR-8), Neuropeptides B/W receptor type 2, Olfactory receptor 2 J3, G protein-coupled receptor, Oxoglutarate (alpha-ketoglutarate) receptor 1, 5-hydroxytryptamine receptor 7 (5-HT7).

As summarized in Table 5, of the 27 CNS proteins homologous to Tg, 2 (7%; nidogen-1/entactin and ephrin type-B receptor 2) were reported to generate autoAb, and in the following conditions: certain types of glomerulonephritis, autoimmune uveoretinitis, systemic lupus erythematosus and related disorders (systemic vasculitis, rheumatoid arthritis), pulmonary renal syndrome, the Aicardi-Goutières syndrome, acute necrotizing encephalopathy, and systemic sclerosis [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62]. As mentioned above (see heading “Topographic position of the homologous proteins with respect to domains and epitopic regions of each thyroid autoantigen”) of the 6 Tg-homologous segments of nidogen-1/entactin (of which one matches the epitopic region of Tg at aa 20–190, and another overlaps with the two epitopic region of Tg 1116–1168 and 1168–1269), four entirely contain the epitope 867–887 (segments 849–917, 847–919, 859–922 and 867–925), while two partially overlap with it (segments 874–919 and 880–919). It is noteworthy that segments 849–917 and 867–925 of nidogen-1, which entirely include an epitope of this protein, are homologous to two segments of Tg which correspond to epitopes of this thyroid autoantigen.

Table 5.

Involvement in autoimmune disorders, as resulting from a PubMed search, of the proteins that we found share local homology with thyroglobulin.

Protein No. of articles Citations Results
Nidogen-1/Entactin 9 Fukatsu A et al. 1987 [52] Rats injected with mercuric chloride develop autoantibodies to various components of the glomerular basement membrane, including emtactin
Saxena R et al. 1990 [53] Entactin is a possible autoantigen of the glomerular basement membrane, which could be involved in some types of human autoimmune glomerulonephritis (non-Goodpasture)
Saxena R et al. 1991 [54] Anti-entactin antibodies were found in extracapillary glomerulonephritis patients, although very few.
Saxena R et al. 1991 [55] Circulating anti-entactin antibodies are present in specific types of glomerulonephritis, but not in others nor in healthy subjects.
Wang J et al. 1994 [56] In the iris of rats with experimental autoimmune uveoretinitis, there is an increase in immunoreactivity of several proteins, including entactin
Saxena R et al. 1994 [57] Patients with systemic lupus erythematosus often have anti-entactin antibodies, which are more common in case of severe disease.
Saxena R et al. 1995 [58] Two of 40 patients with pulmonary renal syndrome had anti-entactin autoantibodies
Li QZ et al. 2005 [59] Autoantibodies to entactin are frequent in patients with lupus but not associated with disease activity
Cuadrado E et al. 2015 [60] IgG antibodies to several autoantigens, including entactin, are present in patients with Aicardi-Goutières syndrome, an autoimmune disorder with some similarities to systemic lupus erythematous which particularly targets the cerebral white matter.
Ephrin type-B receptor 2 2 Shirai T et al. 2013 [61] Autoantibodies to ephrin type B receptor 2 were found in a patient with acute necrotizing encephalopathy and systemic lupus erythematosus, but not in patients with lupus only.
Azzouz DF et al. 2016 [62] Patients with systemic sclerosis or systemic lupus erythematosus show autoantibodies to ephrin type B receptor 2

Of the 27 Tg homologous proteins, 25 do not appear in the Table, because we retrieved no literature about their involvement in autoimmune disorders. These proteins are: Testican-1/Protein SPOCK, Testican-2/SPARC/osteonectin, CWCV, and Kazal-like domains proteoglycan 2 (SPOCK2), SPARC-related modular calcium-binding protein 1/Secreted modular calcium-binding protein 1 (SMOC-1), Testican-3, SPARC-related modular calcium-binding protein 2/Secreted modular calcium-binding protein 2 (SMOC-2), Insulin-like growth factor-binding protein 5, CUB and EGF-like domain-containing protein 1, Ephrin type-B receptor 6, Ephrin type-B receptor 7, Acetylcholinesterase (Yt blood group), Butyrylcholinesterase, Neuroligin-3, Neuroligin-4, X-linked, Neuroligin-4, Y-linked, Neuroligin-1, Carboxylesterase 3 (CES3), Cocaine esterase, Carboxylesterase 5A, Neuroligin-2, Brain carboxylesterase hBr3, Liver carboxylesterase 1/Acyl-coenzyme A:cholesterol acyltransferase/Brain carboxylesterase hBr1/Cocaine carboxylesterase/Egasyn/Methylumbelliferyl-acetate deacetylase 1/Monocyte/macrophage serine esterase/Retinyl ester hydrolase/Serine esterase 1/Triacylglycerol hydrolase, KIAA1480 protein, Carboxylesterase 4A, Carboxylesterase 8 (CES8), KIAA1366 protein.

Concerning ephrin type-B receptor 2, the only Tg-homologous segment (aa 269–312) marginally overlaps with a known epitope (aa 309–318) of the protein, while its Tg counterpart (aa 1473–1531) entirely contains the Tg epitope 1473–1526.

As summarized in Table 6, of the 47 CNS proteins homologous to TPO, 7 (15%; fibrillin-1/asprosin, fibrillin-3, LRP-2, LRP-4, P-selectin/CD62P/granule membrane protein 140/leukocyte-endothelial cell adhesion molecule 3, and the aforesaid nidogen-1/entactin) were reported to generate autoAb, and in the following conditions: recurrent pregnancy loss, pregnancy-induced hypertension, systemic sclerosis, localized scleroderma, CREST (calcinosis, Raynaud's esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome, mixed connective tissue disease, type 1 diabetes mellitus, primary pulmonary hypertension syndrome, myasthenia gravis, autoimmune polyglandular syndrome type 3, amyotrophic lateral sclerosis, ABBA disease (a renal disease characterized by kidney antibrush border antibodies and renal failure), rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Behçet's disease, and idiopathic thrombocytopenic purpura [52], [53], [54], [55], [56], [57], [58], [59], [60], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [84], [85], [86], [87], [88], [89], [90], [91], [92], [93]

Table 6.

Involvement of the proteins that we found share local homology with thyroperoxidase in autoimmune disorders, as resulting from a PubMed search.

Protein No. of articles Citations Results
Fibrillin-1/Asprosin/Epididymis secretory sperm binding protein 11 Atanasova MA et al. 2011 [63] Increased anti-fibrillin-1 IgM antibodies in patients with recurrent pregnancy loss may contribute to the pathogenesis of this condition
Admou B et al. 2009 [64] Anti-fibrillin-1 autoantibodies may be present in systemic sclerosis patients
Grassegger A et al. 2008 [65] Anti-fibrillin-1 autoantibodies seem to have important roles in the pathogenesis of systemic sclerosis
Zhou X et al. 2005 [66] Anti-fibrillin-1 autoantibodies are specifically present in systemic sclerosis patients and may induce activation of normal dermal fibroblasts into a profibrotic phenotype, which resembles that of systemic sclerosis
Nicoloff G et al. 2005 [67] Anti-fibrillin-1 autoantibodies can be found in diabetic patients
Pandey JP et al. 2001 [68] Anti-fibrillin-1 autoantibodies in systemic sclerosis patients are associated with specific KM and GM allotypes (genetic markers of immunoglobulin kappa and gamma chains, respectively)
Tan FK et al. 2000 [69] Anti-fibrillin-1 autoantibodies in systemic sclerosis patients correlate with specific ethnic groups but not HLA alleles
Morse JH et al. 2000 [70] Anti-fibrillin-1 autoantibodies are present in primary pulmonary hypertension, other than in systemic sclerosis, CREST (calcinosis, Raynaud's esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome, mixed connective tissue disease.
Lundberg I et al. 2000 [71] Anti-fibrillin-1 autoantibodies are present in CREST (calcinosis, Raynaud's esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome and mixed connective tissue disease.
Arnett FC et al. 1999 [72] Anti-fibrillin-1 autoantibodies are present in patients with linear scleroderma or morphea.
Tan FK et al. 1999 [73] Anti-fibrillin-1 autoantibodies may be found in patients with systemic sclerosis, CREST (calcinosis, Raynaud's esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome or mixed connective tissue disease.
Low-density lipoprotein receptor-related protein 4 (LRP-4) 12 Inoue H et al. 2020 [74] Case report of a patient affected by myasthenia gravis and autoimmune polyglandular syndrome type 3, with autoantibodies to both acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibody
Park KH et al. 2018 [75] Analysis of multiple autoantibodies (including those to low-density lipoprotein receptor-related protein 4) in patients with myasthenia gravis
Ohnari K et al. 2018 [76] Report of a case of myasthenia gravis and amyotrophic lateral sclerosis, with autoantibodies to acetylcholine receptor and low-density lipoprotein receptor-related protein 4
Kruger JM et al. 2017 [77] Report of a case of myasthenia gravis with autoantibodies to low-density lipoprotein receptor-related protein 4, but not to acetylcholine receptor nor to muscle-specific kinase
Ishikawa H et al. 2017 [78] Report of two cases of myasthenia gravis and invasive thymoma, with autoantibodies to acetylcholine receptor and low-density lipoprotein receptor-related protein 4
Li Y et al. 2017 [79] Identification of autoantibodies to low-density lipoprotein receptor-related protein 4 in Chinese patients with myasthenia gravis
Takahashi H et al. 2016 [80] Report of two cases of amyotrophic lateral sclerosis with autoantibodies to low-density lipoprotein receptor-related protein 4, who showed myasthenic symptoms
Marino M et al. 2015 [81] Analysis of the presence of autoantibodies to low-density lipoprotein receptor-related protein 4 in an Italian cohort of 101 myasthenic patients, 45 healthy blood donors and 40 patients with other neurological diseases
Zisimopoulou P et al. 2014 [82] Autoantibodies to low-density lipoprotein receptor-related protein 4 were found in 18.7% of about 800 patients with myasthenia gravis from 10 countries
Zouvelou V et al. 2013 [83] Report of two cases of myasthenia gravis with autoantibodies to low-density lipoprotein receptor-related protein 4, but not to acetylcholine receptor nor to muscle-specific kinase
Motomura M et al. 2012 [84] Autoantibodies to low-density lipoprotein receptor-related protein 4 were found in 9/300 patients with generalized myasthenia gravis negative for anti- acetylcholine receptor autoantibodies
Higuchi O et al. 2011 [85] First report of the presence and pathogenetic role of autoantibodies to low-density lipoprotein receptor-related protein 4 in patients with myasthenia gravis
Fibrillin-3 1 Dolcino M et al. 2014 [86] The peptide TNRRGRGSPGAL, recognized by nearly all sera of patients with psoriatic arthritis, shows amino acid sequence homology and cross-reacts with some skin autoantigens, including fibrillin-3.
fibrillin 1 variant, partial 11 Atanasova MA et al. 2011 [63] Increased anti-fibrillin-1 IgM antibodies in patients with recurrent pregnancy loss may contribute to the pathogenesis of this condition
Admou B et al. 2009 [64] Anti-fibrillin-1 autoantibodies may be present in systemic sclerosis patients
Grassegger A et al. 2008 [65] Anti-fibrillin-1 autoantibodies seem to have important roles in the pathogenesis of systemic sclerosis
Zhou X et al. 2005 [66] Anti-fibrillin-1 autoantibodies are specifically present in systemic sclerosis patients and may induce activation of normal dermal fibroblasts into a profibrotic phenotype, which resembles that of systemic sclerosis
Nicoloff G et al. 2005 [67] Anti-fibrillin-1 autoantibodies can be found in diabetic patients
Pandey JP et al. 2001 [68] Anti-fibrillin-1 autoantibodies in systemic sclerosis patients are associated with specific KM and GM allotypes (genetic markers of immunoglobulin kappa and gamma chains, respectively)
Tan FK et al. 2000 [69] Anti-fibrillin-1 autoantibodies in systemic sclerosis patients correlate with specific ethnic groups but not HLA alleles
Morse JH et al. 2000 [70] Anti-fibrillin-1 autoantibodies are present in primary pulmonary hypertension, other than in systemic sclerosis, CREST (calcinosis, Raynaud's esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome, mixed connective tissue disease.
Lundberg I et al. 2000 [71] Anti-fibrillin-1 autoantibodies are present in CREST (calcinosis, Raynaud's esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome and mixed connective tissue disease.
Arnett FC et al. 1999 [72] Anti-fibrillin-1 autoantibodies are present in patients with linear scleroderma or morphea.
Tan FK et al. 1999 [73] Anti-fibrillin-1 autoantibodies may be found in patients with systemic sclerosis, CREST (calcinosis, Raynaud's esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome or mixed connective tissue disease.
Low-density lipoprotein receptor-related protein 2 (LRP-2) 5 Larsen CP et al. 2018 [87] Autoantibodies to low-density lipoprotein receptor-related protein 2 can be found in patients with ABBA disease, a kidney disease characterized by kidney antibrush border antibodies and renal failure.
Ooka S et al. 2003 [88] Autoantibodies to low-density lipoprotein receptor-related protein 2 were found in patients with rheumatoid arthritis (87%), systemic lupus erythematosus (40%), systemic sclerosis (35%), osteoarthritis (15%), Behçet's disease (3%)
Dinesh KP et al. 2019 [89] Report of a case of anti-LRP2 nephropathy/anti-brush border antibody disease
Yu X et al. 2001 [90] Detection of amino acid sequence homology and cross-reactivity between CD69 and low-density lipoprotein receptor-related protein 2
Illies F et al. 2004 [91] Report of a patient with autoimmune thyroiditis and membranous nephropathy; low-density lipoprotein receptor-related protein 2 (megalin) is expressed on thyroid cells in a TSH-dependent manner and could be a link between the two diseases
P-selectin (CD62P)/Granule membrane protein 140/Leukocyte-endothelial cell adhesion molecule 3/Platelet activation dependent granule-external membrane protein 2 Jiang H et al. 1993 [92] Autoantibodies to granule membrane protein 140 were found in 13/46 patients with severe pregnancy-induced hypertension
Zhang S et al. 1995 [93] Autoantibodies to granule membrane protein 140 were found in 17/92 patients with idiopathic thrombocytopenic purpura
Nidogen-1/Entactin 9 Fukatsu A et al. 1987 [52] Rats injected with mercuric chloride develop autoantibodies to various components of the glomerular basement membrane, including emtactin
Saxena R et al. 1990 [53] Entactin is a possible autoantigen of the glomerular basement membrane, which could be involved in some types of human autoimmune glomerulonephritis (non-Goodpasture)
Saxena R et al. 1991 [54] Anti-entactin antibodies were found in extracapillary glomerulonephritis patients, although very few.
Saxena R et al. 1991 [55] Circulating anti-entactin antibodies are present in specific types of glomerulonephritis, but not in others nor in healthy subjects.
Wang J et al. 1994 [56] In the iris of rats with experimental autoimmune uveoretinitis, there is an increase in immunoreactivity of several proteins, including entactin
Saxena R et al. 1994 [57] Patients with systemic lupus erythematosus often have anti-entactin antibodies, which are more common in case of severe disease.
Saxena R et al. 1995 [58] Two of 40 patients with pulmonary renal syndrome had anti-entactin autoantibodies
Li QZ et al. 2005 [59] Autoantibodies to entactin are frequent in patients with lupus but not associated with disease activity
Cuadrado E et al. 2015 [60] IgG antibodies to several autoantigens, including entactin, are present in patients with Aicardi-Goutières syndrome, an autoimmune disorder with some similarities to systemic lupus erythematous which particularly targets the cerebral white matter.

Of the 47 TPO homologous proteins, 40 do not appear in the Table, because we retrieved no literature about their involvement in autoimmune disorders. These proteins are: Peroxidasin homolog/Melanoma-associated antigen MG50/Vascular peroxidase 1, Peroxidasin-like protein, Prostaglandin G/H synthase 2/Cyclooxygenase-2, Prostaglandin G/H synthase 1/Cyclooxygenase-1, Adhesion G protein-coupled receptor E2/EGF-like module receptor 2/CD312, Protocadherin Fat 4, Latent-transforming growth factor beta-binding protein 4 (LTBP4), Latent-transforming growth factor beta-binding protein 1 (LTBP-1), Seizure related 6-like protein 2, CUB and sushi domain-containing protein 1, C-type lectin domain family 14 member A/Epidermal growth factor receptor 5 (EGFR-5), Multiple epidermal growth factor-like domains protein 6, Seizure 6-like protein/KIAA0927 protein, Cadherin EGF LAG seven-pass G-type receptor 2/Cadherin family member 10/Flamingo homolog 3, EGF-containing fibulin-like extracellular matrix protein 2, Nephronectin/Preosteoblast EGF-like repeat protein with MAM domain/EGFL6-like, Complement component C1q receptor/CD93, Fibulin 5, Tolloid-like protein 1, EGF-containing fibulin-like extracellular matrix protein 1, Signal peptide, CUB and EGF-like domain-containing protein 1, Latent-transforming growth factor beta-binding protein 1 (LTBP1), KIAA1237 protein, partial, Vitamin K-dependent protein S, Protein HEG homolog 1, Low-density lipoprotein receptor-related protein 1B (LRP-1B), Fibulin-1, Fibulin 1, Protein kinase C-binding protein NELL2, NOTCH4 protein, complement receptor type 2, dual oxidase 2 precursor variant, partial, CSMD2 protein, Cysteine-rich with EGF-like Domains 2 (CRELD2) beta, Endosialin/CD248, Prolow-density lipoprotein receptor-related protein 1/Alpha-2-macroglobulin receptor/Apolipoprotein E receptor/CD91, CUB and sushi domain-containing protein 3, Thrombospondin-3, Epidermal growth factor-like protein 6, Mutant p53 binding protein 1 variant, partial.

Of interest, it was found that the random peptide TNRRGRGSPGAL, which Dolcino et al. found to be recognized by nearly all sera of patients with psoriatic arthritis, shows amino acid sequence homology and cross-reacts with some skin autoantigens, including fibrillin-3 [86]. Of the 22 TPO-homologous segments of fibrillin-1, seven contained, or had some overlap with, an epitope of the protein. In the majority of cases, the autoantigenic peptide reported in literature had some modifications (citrullinated, methylated or cysteinylated). In detail, segment 723–765 contained the epitopes 733–748 (citrullinated in R11) and 737–752 (citrullinated in R7), segment 908–952 contained the epitopes 917–932 (citrullinated in R14), 921–936 (citrullinated in R10), 925–940 (citrullinated in R6) and almost all of the epitope 947–955 (cysteinylated in C4), segment 1174–1238 contained the epitope 1186–1194 and the epitope 1203–1211 (which is reported in literature in two versions, without or with methylation in C6), segment 1216–1280 contained the epitope 1256–1264 (methylated in C8), segment 2289–2334 contained the epitopes 2301–2316 (citrullinated in R6 and R11), 2305–2320 (citrullinated in R2 and R7) and 2309–2324 (citrullinated in R3); segments 1645–1692 and 2413–2507 had rather limited overlap with epitopes 1689–1697 (methylated in C7) and 2502–2510 (methylated in C8), respectively. All parts of TPO homologous to fibrosin-1 had insignificant (5 aa or less) or no overlap with known TPO epitopes, with one exception (segment 740–832, matching aa 2129–2199 of fibrosin-1, contains the entire TPO epitope 766–775 and part of epitope 842–861).

The 17 TPO-homologous segments of fibrillin-3 contained an epitope in four cases, while their TPO counterparts had four complete and one partial overlap with an epitope. The only match between two epitope-containing segments was that between aa 2368–2468 of fibrillin-3 (which include the epitope 2425–2440, citrullinated in R9, and 2429–2444, citrullinated in R5 and R14) and aa 762–782 of TPO (which include the epitope 766–775). The segment 763–816 of fibrillin-3 (which contains the epitope 773–786) matched segment 793–852 of TPO, which has an 11-residue overlap with the autoepitope 842–861 of the protein. The epitope-containing segments without an epitope-containing homolog were localized at positions 570–614 (containing epitope 594–602) and 867–911 (containing epitope 878–886) of fibrillin-3, and positions 794–866, 795–862 (both containing epitope 842–861) and 766–831 (containing epitope 766–775) of TPO. All other homologous segments of both proteins had insignificant or no overlap with known epitopes.

Concerning LRP-2, three TPO-homologous segments were found, of which only one (aa 1388–1428) contained autoepitopes (aa 1397–1412, citrullinated in R12 and R16, and aa 1401–1416, citrullinated in R8 and R12); their TPO counterparts had insignificant or no overlap with known epitopes. Upon describing one patient with AIT and membranous nephropathy, the authors report that low-density lipoprotein receptor-related protein 2 (megalin) is expressed on thyroid cells in a TSH-dependent manner and could be the link between the two diseases [91].

The single local homology found between LRP-4 and TPO involved aa 359–433 of LRP-4, which contain the epitopes 361–376 (citrullinated in R13) and 365–380 (citrullinated in R9), and aa 747–838 of TPO, which contain the epitope 766–775.

A single local homology was found also between P-selectin and TPO, but in this case neither segment (aa 531–621 and 759–843, respectively) contained epitopes (there was only an overlap of few residues in the case of the TPO segment).

Discussion

Expanding our previous data [25], we have provided some evidence for molecular mimicry between thyroid autoantigens and CNS-expressed proteins being a reasonable mechanism for HE/SREAT. First, a limited number of CNS-expressed proteins match relatively short to relatively long sequences of the thyroid autoantigens. Second, the homologous sequences of the three thyroid autoantigens almost always contain at least one epitope. Third, the CNS areas where the thyroid-autoantigen homologous proteins are expressed match CNS areas where abnormalities were detected at biopsy/necropsy and/or by neuroimaging in patients with HE/SREAT. Fourth, the literature associated a number of the homologous CNS-expressed proteins with a number of autoimmune disorders (not necessarily CNS-restricted), in which corresponding serum autoAb were detected.

TSH-R belongs to the superfamily of the rhodopsin-like G protein-coupled receptors (GPCR), whose ectodomain belongs, in turn, to the family of proteins with leucine-rich repeats (LRR) [94]. Thus, many of the homologies found (Table 1, Fig. 2) were not unexpected. Interestingly, the TSH-R regions of homology involve its nine LRR repeats, the serpentine domain (aa 414–682, with seven transmembrane helices) and most of the cytoplasmic tail (aa 683–764). Further to the last 20 residues (aa 745–764), two other TSH-R regions are spared by homologies: the signal peptide (first 20 residues) and, upon ignoring LGR4, LGR5, LGR7 and LGR8, the region 255–369. This last region encompasses the LRR9 repeat at 250–271 and most of the hinge region (aa 272–413) with its TSH-R specific sequence at aa 317–366. This segment 317–366 (also called the 50-residue long C-peptide of TSH-R), that is deleted following an intramolecular cleavage, is TSH-R specific because it is absent in the cognate gonadotropin receptors (FSH-R, LH-R) [95].

Assuming that the CNS-expressed TSH-R undergoes the same intramolecular cleavage as the thyrocyte-expressed TSH-R, then the CNS cell will continue to have a cell-attached TSH-R, so called B subunit, with a few extracellular residues distal to the cleaved 317–366 segment, the whole serpentine domain and the intracellular C-terminus. This approximately 400-residue long portion of TSH-R will retain zones of homology with alpha-enolase, AKRIA and several CNS-expressed proteins, as well as a number of epitopes. Most of these epitopes bind TSH-R Ab that inhibit the TSH-R signaling. Thus, it is possible that, whatever the function(s) of TSH-R may be in the CNS, binding to these Ab might inhibit such function(s).

Also not surprising is the presence of esterases in the list of proteins omologous to the C-terminal part of Tg, because the segment starting at aa 2188 is the acetylcholinesterase domain of this thyroid autoantigen. As reported by Veneziani et al. [96]type I repeats of Tg share varying degrees of homology with a six-residue cysteine motif found in a variety of proteins. These include: …. the cell-adhesion protein nidogen/entactin, the insulin-like growth factor binding protein (IGFBP), … the proteoglycan testican…”. Moreover, “The cysteine-rich units of Tg share limited structural analogy with the epidermal growth factor (EGF-) homologous repeats found, in single or multiple copies, in a variety of proteins… The homology between EGF-like modules is based primarily on the position of six cysteins (numbered Cys1 through CysVI). Type I repeats of Tg differ from typical EGF-like modules for the spacings between some of the cysteines, and the presence of unrelated inserts of variable length at conserved positions”.

Finally, because TPO belongs to the Haem peroxidase superfamily, namely haem-containing enzymes that use hydrogen peroxide as the electron acceptor to catalyse oxidative reactions (http://www.ebi.ac.uk/interpro/entry/IPR019791), homologies with peroxidasins, prostaglandin G/H synthases/cyclooxygenases, dual oxidase 2 were expected. In addition, the stretch 742–795 of TPO contains SUSHI repeats that have been identified in several proteins of the complement system, while aa 796–838 is the calcium-binding EGF domain (https://www.ncbi.nlm.nih.gov/protein/AAA61217.2). Accordingly, also not unexpected were the homologies with complement component C1q receptor, CUB and sushi domain-containing proteins (including seizure related 6-like proteins), CUB and EGF-like domain-containing proteins (including Tolloid-like protein 1), endosialin/CD248 (a protein with one EGF-like domain and one sushi domain), P-selectin (CD62P)/granule membrane protein 140/leukocyte-endothelial cell adhesion molecule 3/platelet activation dependent granule-external membrane protein (a protein with one EGF-like domain and multiple sushi domains), cysteine-rich with EGF-like domains 2 beta, adhesion G protein-coupled receptor E2/EGF-like module receptor 2, EGF-containing fibulin-like extracellular matrix proteins, nephronectin/preosteoblast EGF-like repeat protein with MAM domain/EGFL6-like, multiple EGF-like domains protein 6, C-type lectin domain family 14 member A/EGF receptor 5 (EGFR-5), and other proteins with multiple EGF-like domains (fibrillins, protocadherin fat 4, low-density lipoprotein receptor-related proteins, latent-transforming growth factor beta-binding proteins, fibulins, protein HEG homolog 1, protein kinase C-binding protein NELL2, NOTCH4, thrombospondin-3, and nidogen-1/entactin). Of note, aa 846–919 of nidogen 1/entactin correspond to the Tg type 1 repeat domain of this sulfated glycoprotein widely distributed in basement membranes and tightly associated with laminin (https://www.uniprot.org/uniprot/P14543).

Among CNS proteins homologous to TPO, low-density lipoprotein receptor-related protein 4 (LRP4) deserves particular attention. LRP4 has a central role in synaptic development and maintenance, and acts as the muscle receptor for neural agrin, propagating the signal to muscular tyrosin kinase receptors (MuSK) for acetylcholine receptors (AChR) clustering at the neuromuscular junction (NMJ), a peripheral cholinergic synapse between motor neurons and skeletal muscle fibers [97]. LRP4 autoantibodies are detected in some patients with myasthenia gravis (MG), and the inhibition of the LRP4-agrin interaction appears to be responsible, at least in part, for their pathogenicity [98]. In a systematic review, autoimmune thyroid disease was the most frequent of 23 associated autoimmune disorders, occurring in 10% of MG patients [99]. LRP4 antibodies have also been detected in 10–23% of amyotrophic lateral sclerosis (ALS) patients [100], [101]

As to the NMJ, neurotransmission in the CNS requires precise control of neurotransmitter release from presynaptic terminals and responsiveness of neurotransmitter receptors on postsynaptic membrane, and this process is regulated by glial cells; however, underlying mechanisms are not fully understood. Being expressed in the brain, LRP4 has been implicated in hippocampal synaptic plasticity [102], [103]. It has been demonstrated that glutamate release in the hippocampal regions of the brain is impaired in LRP4-defective mice, revealing a critical role of the LRP4-agrin signaling in modulating astrocytic ATP release and synaptic glutamatergic transmission [103], [104]. More recently, it has been demonstrated that LRP4 is reduced in the brain of patients with Alzheimer disease (AD), paralleling the reduced levels in an AD mouse model that are associated with exacerbation of cognitive impairment and increases in the amount of amyloid aggregates [105]. Impaired synaptogenesis and altered synaptic transmission at the temporal regions are commonly associated with cognitive disturbances, behavioural alterations, memory reduction. All the above-mentioned disturbances are likewise described in HE/SREAT. Hence, in the light of the of homology between LRP4 and TPO, and considering that presence of LRP4 in temporal areas of the brain has been described, we could speculate on a possible cross reactivity between anti-TPO antibodies and LRP4, explaining the cognitive and behavioural manifestations of HE/SREAT.

The multiform clinical symptomatology of SREAT and its dramatic responsiveness to the corticosteroid therapy (as also supported by the disappearance of abnormalities detected at neuroimaging and electroencephalography, in parallel with a fall both in the serum and CSF levels of the pre-therapy markedly elevated thyroid Ab levels), is better explained by the following scenario. Prior to therapy, elevated levels of thyroid Ab (viz. any of TgAb, TPOAb and TSH-R-Ab) would gain access to the CSF through a damaged blood–brain-barrier. Not only, as we explained previously [25], any of these thyroid Ab can attack CNS cells that express the corresponding autoantigen (viz. any of Tg, TPO, TSH-R) but it/they may attack cells that express one or more of CNS-expressed proteins described here and previously [25]. A requisite for this last attack and associated Ab binding with at least one of these proteins is that the thyroid Ab has/have been elicited by one or more epitopes contained in regions of the thyroid autoantigen that share homology with such CNS protein(s). As shown in this paper, a given region of a given thyroid autoantigen can share homology with only one, a few or several CNS-expressed proteins. Hence, it would be hard to find two HE/SREAT patients with the same panel of symptoms. Once steroid therapy has knocked-down thyroid Ab levels and thyroid Ab passage into the CNS, then attacks to the above CNS cells would terminate and symptomatology, neuroimaging and electroencephalography abnormalities disappear.

CNS proteins that share a series of homologies with antibodies associated to HE/SREAT have a prevalent distribution in areas correlated with the limbic system and temporal regions in general, as also supported by the literature data on neuroradiological alterations which are prevalent in these regions in HE/SREAT patients (Supplementary Table 1, Table 2, Table 3). This could justify some symptoms, such as confusion, behavior and memory disorders, and epilepsy. In our study, homologies are also detectable among some proteins located in the blood–brain barrier (BBB) (i.e. proteins of the Notch families) and HE/SREAT associated antibodies target, determining a BBB damage and suggesting a possible mechanism of brain aggression by autoantibodies and immunocompetent cells.

A similar mechanism could only be suggested also for cerebellar ataxia in HE/SREAT. In fact, the intimate pathological mechanism underlying cerebellar ataxia development in HE/SREAT has already been investigated, however it remains obscure; an impaired presynaptic short-term plasticity between parallel fiber-Purkinje cell transmissions and defective glutamate release have been postulated as potential pathological mechanisms in some patients with HE/SREAT [106], [107].

The spatial position of the homologous segments in relation to cell compartments (extracellular, transmembrane, intracellular) and in the context of the three-dimensional structure of the respective proteins (conformation and chemical characteristics of protein surface, degree of solvent exposure) may be important in the pathogenesis of autoimmune diseases. As a general rule, autoantibodies against extracellular, solvent exposed parts of a molecule are more often directly pathogenetic, while the role of autoimmunity against parts of the molecules that are normally “hidden” from the immune system is less straightforward.

Some authors compared autoimmune conditions characterized by intracellular and extracellular target autoantigens, pointing out differences and possible implications of this difference in clinical, monitoring, diagnostic and therapeutic terms [108]. By analogy, these considerations could be applied to autoimmunity against exposed and hidden parts of molecules, and this aspect, currently unexplored, could be an intriguing line of future research in the field of SREAT.

In conclusion, we support our idea of HE/SREAT being ignited by thyroid autoantigens that, after having gained access to CS, bind to Tg, TPO and TSH-R expressed in cells of the CNS [25] forming immune complexes. In addition to this mechanism, it is well possible that TgAb, TPOAb, TSH-R-Ab may cross-react with CNS-expressed proteins that share local homology with the corresponding thyroid autoantigens. Depending on the prevalent thyroid Ab that forms the immune complex, the homologous protein(s) that cross-react(s), the CNS area(s) and cell(s) expressing such homologous protein(s) and the resulting impairment of its/their function(s), given symptoms will appear, thus explaining the notoriously multiform clinical presentation and neuroradiological abnormalities of HE/SREAT. If one admits that pathogenicity ensues from TgAb, TPOAb, TSH-R-Ab that gain access to the CNS and the necessity of such Ab to be directed against epitopes that are shared with the corresponding CNS-expressed homologous protein(s), then the probability of occurrence of such epitope requisite would be relatively rare. This rarity fits with the knowledge of HE/SREAT being a rare event compared with the high frequency of HT, the most prevalent autoimmune disease.

At the very minimum, we believe that our data will prompt a number of investigations to directly prove the involvement in HE/SREAT of at least some of the CNS-proteins having homology with the thyroid autoantigens. For instance, one straighforward implication is to check serum thyroid Ab (any of TSH-RAb, TgAb, TPOAb) detected in patients with SREAT for cross-reactivity with the corresponding homogous CNS-proteins (TSH-R-homologous, Tg-homologous, TPO-homologous). Another straightforward translational implication of our data is to characterize epitopically serum thyroid autoantibodies in patients with HT and GD (both TgAb and TPOAb in HT, and at least TSH-RAb in GD). If any of these serum Ab recognize epitopes of the corresponding thyroid autoantigen that fall in regions sharing homology with any of the known HT/SREAT autoantigens (alpha-enolase, AKRIA, DDAHI) and/or any of the CNS-expressed proteins we report here, once it/they has/have been proved as autoantigens associated with HT/SREAT, then HT or GD patients can be sorted out in terms of risk for HT/SREAT.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

Salvatore Benvenga: Conceptualization, Methodology, Data curation, Writing – original draft, Writing – review & editing, Supervision. Alessandro Antonelli: Validation, Writing – review & editing. Poupak Fallahi: Validation, Writing – review & editing. Carmen Bonanno: Validation, Data curation, Writing – original draft. Carmelo Rodolico: Validation, Data curation, Writing – original draft. Fabrizio Guarneri: Formal analysis, Investigation, Writing – original draft, Visualization.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Footnotes

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jcte.2021.100274.

Appendix A. Supplementary data

The following are the Supplementary data to this article:

Supplementary data 1
mmc1.doc (118.5KB, doc)
Supplementary data 2
mmc2.doc (88.5KB, doc)
Supplementary data 3
mmc3.doc (130.5KB, doc)
Supplementary data 4
mmc4.doc (30KB, doc)

References

  • 1.Brain L., Jellinek E.H., Ball K. Hashimoto’s disease and encephalopathy. Lancet. 1966;288:512–514. doi: 10.1016/s0140-6736(66)92876-5. [DOI] [PubMed] [Google Scholar]
  • 2.Sawka A.M., Fatourechi V., Boeve B.F., Mokri B. Rarity of encephalopathy associated with autoimmune thyroiditis: a case series from Mayo Clinic from 1950 to 1996. Thyroid. 2002;12:393–398. doi: 10.1089/105072502760043477. [DOI] [PubMed] [Google Scholar]
  • 3.Melcescu E, Horton WB, Pitman KT, Vijayakumar V, Koch CA. Euthyroid Graves' orbitopathy and incidental papillary thyroid microcarcinoma. Hormones (Athens) 2013;12:298-304. 10.14310/horm.2002.1414. [DOI] [PubMed]
  • 4.Melcescu E., Horton W.B., Kim D., Vijayakumar V., Corbett J.J., Crowder K.W., et al. Graves orbitopathy: update on diagnosis and therapy. South Med J. 2014;107:34–43. doi: 10.1097/SMJ.0000000000000038. [DOI] [PubMed] [Google Scholar]
  • 5.Kothbauer-Margreiter I., Sturzenegger M., Komor J., Baumgartner R., Hess C.W. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol. 1996;243:585–593. doi: 10.1007/BF00900946. [DOI] [PubMed] [Google Scholar]
  • 6.Ochi H., Horiuchi I., Araki N., Toda T., Araki T., Sato K., et al. Proteomic analysis of human brain identifies alpha-enolase as a novel autoantigen in Hashimoto's encephalopathy. FEBS Lett. 2002;528:197–202. doi: 10.1016/s0014-5793(02)03307-0. [DOI] [PubMed] [Google Scholar]
  • 7.Yoneda M., Fujii A., Ito A., Yokoyama H., Nakagawa H., Kuriyama M. High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto's encephalopathy. J Neuroimmunol. 2007;185:195–200. doi: 10.1016/j.jneuroim.2007.01.018. [DOI] [PubMed] [Google Scholar]
  • 8.Gini B., Lovato L., Cianti R., Cecotti L., Marconi S., Anghileri E., et al. Novel autoantigens recognized by CSF IgG from Hashimoto's encephalitis revealed by a proteomic approach. J Neuroimmunol. 2008;196:153–158. doi: 10.1016/j.jneuroim.2008.02.015. [DOI] [PubMed] [Google Scholar]
  • 9.Naicker M., Naidoo S. Expression of thyroid-stimulating hormone receptors and thyroglobulin in limbic regions in the adult human brain. Metab Brain Dis. 2018;33:481–489. doi: 10.1007/s11011-017-0076-3. [DOI] [PubMed] [Google Scholar]
  • 10.Chong J.Y., Rowland L.P., Utiger R.D. Hashimoto encephalopathy. syndrome or myth? Arch Neurol. 2003;60:164–171. doi: 10.1001/archneur.60.2.164. [DOI] [PubMed] [Google Scholar]
  • 11.Nolte K.W., Unbehaun A., Sieker H., Kloss T.M., Paulus W. Hashimoto encephalopathy: a brainstem vasculitis? Neurology. 2000;54:769–770. doi: 10.1212/wnl.54.3.769. [DOI] [PubMed] [Google Scholar]
  • 12.Shibata N, Yamamoto Y, Sunami N, Suga M, Yamashita Y. Isolated angiitis of the CNS associated with Hashimoto’s disease. Rinsho Shinkeigaku 1992;32:191-8. N/A. [PubMed]
  • 13.Perrot X, Giraud P, Biacabe AG, Perret-Liaudet A, Borson-Chazot F, Gray F, et al. Hashimoto's encephalopathy: an anatomicoclinical observation. Rev Neurol (Paris) 2002;158:461-6. RN-04-2002-158-4-0035-3787-101019-ART8. [PubMed]
  • 14.Oide T., Tokuda T., Yazaki M., Watarai M., Mitsuhashi S., Kaneko K., et al. Anti-neuronal autoantibody in Hashimoto's encephalopathy: neuropathological, immunohistochemical, and biochemical analysis of two patients. J Neurol Sci. 2004;217:7–12. doi: 10.1016/j.jns.2003.08.005. [DOI] [PubMed] [Google Scholar]
  • 15.Doherty C.P., Schlossmacher M., Torres N., Bromfield E., Samuels M.A., Folkerth R. Hashimoto’s encephalopathy mimicking Creutzfeldt-Jakob disease: brain biopsy findings. J Neurol Neurosurg Psychiatry. 2002;73:601–602. doi: 10.1136/jnnp.73.5.601-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Duffey P., Yee S., Reid I.N., Bridges L.R. Hashimoto's encephalopathy: postmortem findings after fatal status epilepticus. Neurology. 2003;61:1124–1126. doi: 10.1212/01.wnl.0000090462.62087.a1. [DOI] [PubMed] [Google Scholar]
  • 17.Castillo P., Woodruff B., Caselli R., Vernino S., Lucchinetti C., Swanson J., et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006;63:197–202. doi: 10.1001/archneur.63.2.197. [DOI] [PubMed] [Google Scholar]
  • 18.Tsai S.L., Lewis E.C., Sell E., Whiting S. Central nervous system vasculitis with positive antithyroid antibodies in an adolescent boy. Pediatr Neurol. 2011;45:189–192. doi: 10.1016/j.pediatrneurol.2011.04.012. [DOI] [PubMed] [Google Scholar]
  • 19.Uwatoko H., Yabe I., Sato S., Abe M., Shirai S., Takahashi I., et al. Hashimoto's encephalopathy mimicking a brain tumor and its pathological findings: A case report. J Neurol Sci. 2018;394:141–143. doi: 10.1016/j.jns.2018.09.008. [DOI] [PubMed] [Google Scholar]
  • 20.Rukmangadachar L.A., Dandapat S., Bit-Ivan E.N., Peng Y.Y. Hashimoto's encephalopathy – presenting with epilepsia partialis continua and a frontal lobe lesion. Clin Case Rep. 2018;6:136–142. doi: 10.1002/ccr3.1306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Zhao W., Li J., Wang J., Guo Y., Tuo H., Kang Z., et al. A case of Hashimoto encephalopathy: clinical manifestation, imaging, pathology, treatment, and prognosis. Neurologist. 2011;17:141–143. doi: 10.1097/NRL.0b013e3182173341. [DOI] [PubMed] [Google Scholar]
  • 22.Khemka D., Ali J.A., Koch C.A. Primary hypothyroidism associated with acute mania: case series and literature review. Exp Clin Endocrinol Diabetes. 2011;119:513–517. doi: 10.1055/s-0031-1277137. [DOI] [PubMed] [Google Scholar]
  • 23.Steiner J., Schiltz K., Stoecker W., Teegen B., Dobrowolny H., Meyer-Lotz G., et al. Association of thyroid peroxidase antibodies with anti-neuronal surface antibodies in health, depression and schizophrenia - Complementary linkage with somatic symptoms of major depression. Brain Behav Immun. 2020;90:47–54. doi: 10.1016/j.bbi.2020.07.039. [DOI] [PubMed] [Google Scholar]
  • 24.Guldvog I., Reitsma L.C., Johnsen L., Lauzike A., Gibbs C., Carlsen E., et al. Thyroidectomy versus medical management for euthyroid patients with Hashimoto disease and persisting symptoms: a randomized trial. Ann Intern Med. 2019;170:453–464. doi: 10.7326/M18-0284. [DOI] [PubMed] [Google Scholar]
  • 25.Benvenga S., Guarneri F. Homology between TSH-R/Tg/TPO and Hashimoto's encephalopathy autoantigens. Front Biosci (Landmark Ed) 2020;25:229–241. doi: 10.2741/4804. [DOI] [PubMed] [Google Scholar]
  • 26.Benvenga S., Santarpia L., Trimarchi F., Guarneri F. Human thyroid autoantigens and proteins of Yersinia and Borrelia share amino acid sequence homology that includes binding motifs to HLA-DR molecules and T-cell receptor. Thyroid. 2006;16:225–236. doi: 10.1089/thy.2006.16.225. [DOI] [PubMed] [Google Scholar]
  • 27.Guarneri F., Carlotta D., Saraceno G., Trimarchi F., Benvenga S. Bioinformatics support the possible triggering of autoimmune thyroid diseases by Yersinia enterocolitica outer membrane proteins homologous to the human TSH receptor. Thyroid. 2011;21:1283–1284. doi: 10.1089/thy.2010.0364. [DOI] [PubMed] [Google Scholar]
  • 28.Gregoric E., Gregoric J.A., Guarneri F., Benvenga S. Injections of Clostridium botulinum neurotoxin A may cause thyroid complications in predisposed persons based on molecular mimicry with thyroid autoantigens. Endocrine. 2011;39:41–47. doi: 10.1007/s12020-010-9410-9. [DOI] [PubMed] [Google Scholar]
  • 29.Vita R., Guarneri F., Agah R., Benvenga S. Autoimmune thyroid disease elicited by NY-ESO-1 vaccination. Thyroid. 2014;24:390–394. doi: 10.1089/thy.2013.0170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Marangou A., Guarneri F., Benvenga S. Graves' disease precipitated by rickettsial infection. Endocrine. 2015;50:828–829. doi: 10.1007/s12020-015-0767-7. [DOI] [PubMed] [Google Scholar]
  • 31.Benvenga S., Guarneri F. Molecular mimicry and autoimmune thyroid disease. Rev Endocr Metab Disord. 2016;17:485–498. doi: 10.1007/s11154-016-9363-2. [DOI] [PubMed] [Google Scholar]
  • 32.Altschul S.F., Madden T.L., Schäffer A.A., Zhang J., Zhang Z., Miller W., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389–3402. doi: 10.1093/nar/25.17.3389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Gentile F., Conte M., Formisano S. Thyroglobulin as an autoantigen: what can we learn about immunopathogenicity from the correlation of antigenic properties with protein structure? Immunology. 2004;112:13–25. doi: 10.1111/j.1365-2567.2004.01861.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Bresson D., Rebuffat S.A., Péraldi-Roux S. Localization of the immunodominant region on human thyroid peroxidase in autoimmune thyroid diseases: an update. J Autoimmune Dis. 2005;2:2. doi: 10.1186/1740-2557-2-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Le S.N., Porebski B.T., McCoey J., Fodor J., Riley B., Godlewska M., et al. Modelling of thyroid peroxidase reveals insights into its enzyme function and autoantigenicity. PLoS ONE. 2015;10 doi: 10.1371/journal.pone.0142615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.National Institute of Allergy and Infectious Diseases. The Immune Epitope Database (IEDB), http://www.iedb.org; 2020 [accessed 8 October 2020].
  • 37.Papatheodorou I., Moreno P., Manning J., Fuentes A.M., George N., Fexova S., et al. Expression Atlas update: from tissues to single cells. Nucleic Acids Res. 2020;48(D1):D77–D83. doi: 10.1093/nar/gkz947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Greer J.M., Broadley S., Pender M.P. Reactivity to novel autoantigens in patients with coexisting central nervous system demyelinating disease and autoimmune thyroid disease. Front Immunol. 2017;8:514. doi: 10.3389/fimmu.2017.00514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Mazzara S., Sinisi A., Cardaci A., Rossi R.L., Muratori L., Abrignani S., et al. Two of them do it better: novel serum biomarkers improve autoimmune hepatitis diagnosis. PLoS ONE. 2015;10 doi: 10.1371/journal.pone.0137927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Wenzel K., Haase H., Wallukat G., Derer W., Bartel S., Homuth V., et al. Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension. PLoS ONE. 2008;3 doi: 10.1371/journal.pone.0003742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Wenzel K., Wallukat G., Qadri F., Hubner N., Schulz H., Hummel O., et al. Alpha1A-adrenergic receptor-directed autoimmunity induces left ventricular damage and diastolic dysfunction in rats. PLoS ONE. 2010;5 doi: 10.1371/journal.pone.0009409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Tanaka S., Matsunaga H., Kimura M., Ki T., Hidaka Y., Takano T., et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol. 2003;141:155–164. doi: 10.1016/s0165-5728(03)00252-2. [DOI] [PubMed] [Google Scholar]
  • 43.Tanaka S., Kuratsune H., Hidaka Y., Hakariya Y., Tatsumi K.I., Takano T., et al. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med. 2003;12:225–230. doi: 10.3892/ijmm.12.2.225. [DOI] [PubMed] [Google Scholar]
  • 44.Macé G., Jaume M., Blanpied C., Stephan L., Coudert J.D., Druet P., et al. Anti-mu-opioid-receptor IgG antibodies are commonly present in serum from healthy blood donors: evidence for a role in apoptotic immune cell death. Blood. 2002;100:3261–3268. doi: 10.1182/blood-2002-01-0055. [DOI] [PubMed] [Google Scholar]
  • 45.Macé G., Blanpied C., Emorine L.J., Druet P., Dietrich G. Morphine-like activity of natural human IgG autoantibodies is because of binding to the first and third extracellular loops of the mu-opioid receptor. J Biol Chem. 1999;274:20079–20082. doi: 10.1074/jbc.274.29.20079. [DOI] [PubMed] [Google Scholar]
  • 46.Macé G., Blanpied C., Emorine L.J., Druet P., Dietrich G. Isolation and characterization of natural human IgG with a morphine-like activity. Eur J Immunol. 1999;29:997–1003. doi: 10.1002/(SICI)1521-4141(199903)29:03&#x0003c;997::AID-IMMU997&#x0003e;3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  • 47.Kroon M.W., Kemp E.H., Wind B.S., Krebbers G., Bos J.D., Gawkrodger D.J., et al. Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo. J Eur Acad Dermatol Venereol. 2013;27:1172–1175. doi: 10.1111/j.1468-3083.2012.04501.x. [DOI] [PubMed] [Google Scholar]
  • 48.Li Q., Lv Y., Li C., Yi X., Long H.A., Qiao H., et al. Vitiligo autoantigen VIT75 is identified as lamin A in vitiligo by serological proteome analysis based on mass spectrometry. J Invest Dermatol. 2011;131:727–734. doi: 10.1038/jid.2010.341. [DOI] [PubMed] [Google Scholar]
  • 49.Gavalas N.G., Gottumukkala R.V., Gawkrodger D.J., Watson P.F., Weetman A.P., Kemp E.H. Mapping of melanin-concentrating hormone receptor 1 B cell epitopes predicts two major binding sites for vitiligo patient autoantibodies. Exp Dermatol. 2009;18:454–463. doi: 10.1111/j.1600-0625.2008.00813.x. [DOI] [PubMed] [Google Scholar]
  • 50.Gottumukkala R.V., Waterman E.A., Herd L.M., Gawkrodger D.J., Watson P.F., Weetman A.P., et al. Autoantibodies in vitiligo patients recognize multiple domains of the melanin-concentrating hormone receptor. J Invest Dermatol. 2003;121:765–770. doi: 10.1046/j.1523-1747.2003.12494.x. [DOI] [PubMed] [Google Scholar]
  • 51.Kemp E.H., Waterman E.A., Hawes B.E., O'Neill K., Gottumukkala R.V., Gawkrodger D.J., et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest. 2002;109:923–930. doi: 10.1172/JCI14643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Fukatsu A., Brentjens J.R., Killen P.D., Kleinman H.K., Martin G.R., Andres G.A. Studies on the formation of glomerular immune deposits in brown Norway rats injected with mercuric chloride. Clin Immunol Immunopathol. 1987;45:35–47. doi: 10.1016/0090-1229(87)90109-7. [DOI] [PubMed] [Google Scholar]
  • 53.Saxena R., Bygren P., Butkowski R., Wieslander J. Entactin: a possible auto-antigen in the pathogenesis of non-Goodpasture anti-GBM nephritis. Kidney Int. 1990;38:263–272. doi: 10.1038/ki.1990.195. [DOI] [PubMed] [Google Scholar]
  • 54.Saxena R., Bygren P., Rasmussen N., Wieslander J. Circulating autoantibodies in patients with extracapillary glomerulonephritis. Nephrol Dial Transplant. 1991;6:389–397. doi: 10.1093/ndt/6.6.389. [DOI] [PubMed] [Google Scholar]
  • 55.Saxena R., Bygren P., Cederholm B., Wieslander J. Circulating anti-entactin antibodies in patients with glomerulonephritis. Kidney Int. 1991;39:996–1004. doi: 10.1038/ki.1991.126. [DOI] [PubMed] [Google Scholar]
  • 56.Wang J., Lin W.L., Essner E., Shichi H., Yelian F.D. Ultrastructural and immunocytochemical studies of iris vessels in rats with experimental autoimmune uveoretinitis. Curr Eye Res. 1994;13:747–754. doi: 10.3109/02713689409047010. [DOI] [PubMed] [Google Scholar]
  • 57.Saxena R., Sturfelt G., Nived O., Wieslander J. Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders. Ann Rheum Dis. 1994;53:659–665. doi: 10.3109/02713689409047010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Saxena R., Bygren P., Arvastson B., Wieslander J. Circulating autoantibodies as serological markers in the differential diagnosis of pulmonary renal syndrome. J Intern Med. 1995;238:143–152. doi: 10.1111/j.1365-2796.1995.tb00912.x. [DOI] [PubMed] [Google Scholar]
  • 59.Li Q.Z., Xie C., Wu T., Mackay M., Aranow C., Putterman C., et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest. 2005;115:3428–3439. doi: 10.1111/j.1365-2796.1995.tb00912.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Cuadrado E., Vanderver A., Brown K.J., Sandza A., Takanohashi A., Jansen M.H., et al. Aicardi-Goutières syndrome harbours abundant systemic and brain-reactive autoantibodies. Ann Rheum Dis. 2015;74:1931–1939. doi: 10.1136/annrheumdis-2014-205396. [DOI] [PubMed] [Google Scholar]
  • 61.Shirai T., Fujii H., Ono M., Watanabe R., Shirota Y., Saito S., et al. A novel autoantibody against ephrin type B receptor 2 in acute necrotizing encephalopathy. J Neuroinflammation. 2013;10:128. doi: 10.1186/1742-2094-10-128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Azzouz D.F., Martin G.V., Arnoux F., Balandraud N., Martin T., Dubucquoi S., et al. Anti-ephrin type-B receptor 2 (EphB2) and anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) autoantibodies in scleroderma and lupus. PLoS ONE. 2016;11 doi: 10.1186/1742-2094-10-128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Atanasova M.A., Konova E.I., Aleksovska T.A., Todorova K.N., Georgieva M.N., Lukanov T.H. Anti-fibrillin-1 autoantibodies in normal pregnancy and recurrent pregnancy loss. Autoimmun Rev. 2011;10:131–136. doi: 10.1016/j.autrev.2010.09.003. [DOI] [PubMed] [Google Scholar]
  • 64.Admou B., Essaadouni L., Amal S., Arji N., Chabaa L., El Aouad R. Autoantibodies in systemic sclerosis: clinical interest and diagnosis approach. Ann Biol Clin (Paris) 2009;67:273–281. doi: 10.1016/j.autrev.2010.09.003. [DOI] [PubMed] [Google Scholar]
  • 65.Grassegger A., Pohla-Gubo G., Frauscher M., Hintner H. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis. Wien Med Wochenschr. 2008;158:19–28. doi: 10.1007/s10354-007-0451-5. [DOI] [PubMed] [Google Scholar]
  • 66.Zhou X., Tan F.K., Milewicz D.M., Guo X., Bona C.A., Arnett F.C. Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the “scleroderma phenotype”. J Immunol. 2005;175:4555–4560. doi: 10.4049/jimmunol.175.7.4555. [DOI] [PubMed] [Google Scholar]
  • 67.Nicoloff G., Angelova M., Nikolov A. Serum fibrillin-antifibrillin immune complexes among diabetic children. Vascul Pharmacol. 2005;43:171–175. doi: 10.1016/j.vph.2005.06.005. [DOI] [PubMed] [Google Scholar]
  • 68.Pandey J.P., Page G.P., Silver R.M., LeRoy E.C., Bona C.A. Anti-fibrillin-1 autoantibodies in systemic sclerosis are GM and KM allotype-restricted. Exp Clin Immunogenet. 2001;18:123–129. doi: 10.1159/000049191. [DOI] [PubMed] [Google Scholar]
  • 69.Tan F.K., Arnett F.C., Reveille J.D., Ahn C., Antohi S., Sasaki T., et al. Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum. 2000;43:2464–2471. doi: 10.1002/1529-0131(200011)43:11&#x0003c;2464::AID-ANR13&#x0003e;3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  • 70.Morse J.H., Antohi S., Kasturi K., Saito S., Fotino M., Humbert M., et al. Fine specificity of anti-fibrillin-1 autoantibodies in primary pulmonary hypertension syndrome. Scand J Immunol. 2000;51:607–611. doi: 10.1046/j.1365-3083.2000.00733.x. [DOI] [PubMed] [Google Scholar]
  • 71.Lundberg I., Antohi S., Takeuki K., Arnett F., Steiner G., Brumeanu T.D., et al. Kinetics of anti-fibrillin-1 autoantibodies in MCTD and CREST syndrome. J Autoimmun. 2000;14:267–274. doi: 10.1006/jaut.2000.0362. [DOI] [PubMed] [Google Scholar]
  • 72.Arnett F.C., Tan F.K., Uziel Y., Laxer R.M., Krafchik B.R., Antohi S., et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. Arthritis Rheum. 1999;42:2656–2659. doi: 10.1002/1529-0131(199912)42:12&#x0003c;2656::AID-ANR22&#x0003e;3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  • 73.Tan FK, Arnett FC, Antohi S, Saito S, Mirarchi A, Spiera H, et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 1999;163:1066-72. N/A. [PubMed]
  • 74.Inoue H., Yamada K., Fujii A., Tomonari T., Mizuno K., Mita K., et al. A patient with fulminant myasthenia gravis is seropositive for both AChR and LRP4 antibodies, complicated by autoimmune polyglandular syndrome type 3. Intern Med. 2020;59:2177–2181. doi: 10.2169/internalmedicine.4708-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Park K.H., Waters P., Woodhall M., Lang B., Smith T., Sung J.J., et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: autoantibody profiles and clinical features. PLoS ONE. 2018;13 doi: 10.1371/journal.pone.0193723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Ohnari K., Okada K., Higuchi O., Matsuo H., Adachi H. Late-onset myasthenia gravis accompanied by amyotrophic lateral sclerosis with antibodies against the acetylcholine receptor and low-density lipoprotein receptor-related protein 4. Intern Med. 2018;57:3021–3024. doi: 10.2169/internalmedicine.0966-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Kruger J.M., Karussis D., Zisimopoulou P., Petrou P. Low-density lipoprotein receptor-related protein 4-positive myasthenia gravis in a double-seronegative, electromyography-negative patient. J Neuroophthalmol. 2017;37:285–286. doi: 10.1097/WNO.0000000000000499. [DOI] [PubMed] [Google Scholar]
  • 78.Ishikawa H., Taniguchi A., Ii Y., Higuchi O., Matsuo H., Nakane S., et al. Double-seropositive myasthenia gravis with acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies associated with invasive thymoma. Neuromuscul Disord. 2017;27:914–917. doi: 10.1016/j.nmd.2017.06.001. [DOI] [PubMed] [Google Scholar]
  • 79.Li Y., Zhang Y., Cai G., He D., Dai Q., Xu Z., et al. Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis. Muscle Nerve. 2017;56:938–942. doi: 10.1002/mus.25591. [DOI] [PubMed] [Google Scholar]
  • 80.Takahashi H., Noto Y.I., Makita N., Kushimura-Okada Y., Ishii R., Tanaka A., et al. Myasthenic symptoms in anti-low- density lipoprotein receptor-related protein 4 antibody-seropositive amyotrophic lateral sclerosis: two case reports. BMC Neurol. 2016;16:229. doi: 10.1186/s12883-016-0758-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Marino M., Scuderi F., Samengo D., Saltelli G., Maiuri M.T., Shen C., et al. Flow cytofluorimetric analysis of anti-LRP4 (LDL receptor-related protein 4) autoantibodies in Italian patients with myasthenia gravis. PLoS ONE. 2015;10 doi: 10.1371/journal.pone.0135378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Zisimopoulou P., Evangelakou P., Tzartos J., Lazaridis K., Zouvelou V., Mantegazza R., et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014;52:139–145. doi: 10.1016/j.jaut.2013.12.004. [DOI] [PubMed] [Google Scholar]
  • 83.Zouvelou V., Zisimopoulou P., Rentzos M., Karandreas N., Evangelakou P., Stamboulis E., et al. Double seronegative myasthenia gravis with anti-LRP 4 antibodies. Neuromuscul Disord. 2013;23:568–570. doi: 10.1016/j.nmd.2013.03.013. [DOI] [PubMed] [Google Scholar]
  • 84.Motomura M., Higuchi O. Progress of myasthenia gravis: discovery of Lrp4 antibodies. Rinsho Shinkeigaku. 2012;52:1303–1305. doi: 10.5692/clinicalneurol.52.1303. [DOI] [PubMed] [Google Scholar]
  • 85.Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69:418–422. doi: 10.1002/ana.22312. [DOI] [PubMed] [Google Scholar]
  • 86.Dolcino M., Lunardi C., Ottria A., Tinazzi E., Patuzzo G., Puccetti A. Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis. PLoS ONE. 2014;9 doi: 10.1371/journal.pone.0115424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Larsen C.P., Trivin-Avillach C., Coles P., Collins A.B., Merchant M., Ma H., et al. LDL receptor-related protein 2 (megalin) as a target antigen in human kidney anti-brush border antibody disease. J Am Soc Nephrol. 2018;29:644–653. doi: 10.1681/ASN.2017060664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Ooka S., Matsui T., Nishioka K., Kato T. Autoantibodies to low-density- lipoprotein-receptor-related protein 2 (LRP2) in systemic autoimmune diseases. Arthritis Res Ther. 2003;5:R174–R180. doi: 10.1186/ar754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Dinesh K.P., Raniele D., Michels K., Avasare R.S., Larsen C.P., Kayton R., et al. Anti-LRP2 nephropathy with abundant IgG4-positive plasma cells: a case report. Am J Kidney Dis. 2019;74:132–137. doi: 10.1053/j.ajkd.2018.12.039. [DOI] [PubMed] [Google Scholar]
  • 90.Yu X., Matsui T., Otsuka M., Sekine T., Yamamoto K., Nishioka K., et al. Anti-CD69 autoantibodies cross-react with low density lipoprotein receptor-related protein 2 in systemic autoimmune diseases. J Immunol. 2001;166:1360–1369. doi: 10.4049/jimmunol.166.2.1360. [DOI] [PubMed] [Google Scholar]
  • 91.Illies F., Wingen A.M., Bald M., Hoyer P.F. Autoimmune thyroiditis in association with membranous nephropathy. J Pediatr Endocrinol Metab. 2004;17:99–104. doi: 10.1515/jpem.2004.17.1.99. [DOI] [PubMed] [Google Scholar]
  • 92.Jiang H, Wu G, Zhang W, Zhao Y, Xi X, Ruan C. Antiplatelet granule membrane protein (GMP-140) autoantibodies detected in plasma from patients with idiopathic thrombocytopenic purpura. Nouv Rev Fr Hematol 1993;35:487-90. N/A. [PubMed]
  • 93.Zhang S, Dong J, Liu B. Evaluation and its clinical significance of anti- platelet granule membrane protein-140 autoantibodies and anticalmodulin antibody in patients with severe pregnancy-induced hypertension. Zhonghua Fu Chan Ke Za Zhi 1995;30:665-7. https://doi.org/N/A. [PubMed]
  • 94.Vassart G. In: Werner & Ingbar’s The Thyroid: a fundamental and clinical text. 10th ed. Braverman L.E., Cooper D.S., editors. Wolters Kluwer, Lippincott Williams & Wilkins; Philadelphia: 2013. The thyrotropin receptor; pp. 162–168. [Google Scholar]
  • 95.Rapoport B., McLachlan S.M. TSH receptor cleavage into subunits and shedding of the A-Subunit; a molecular and clinical perspective. Endocr Rev. 2016;37:114–134. doi: 10.1210/er.2015-1098. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 96.Veneziani B.M., Giallauria F., Gentile F. The disulfide bond pattern between fragments obtained by the limited proteolysis of bovine thyroglobulin. Biochimie. 1999;81:517–525. doi: 10.1016/s0300-9084(99)80104-7. [DOI] [PubMed] [Google Scholar]
  • 97.Kim N., Stiegler A.L., Cameron T.O., Hallock P.T., Gomez A.M., Huang J.H., et al. Lrp4 is a receptor for agrin and forms a complex with MuSK. Cell. 2008;135:334–342. doi: 10.1016/j.cell.2008.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Lazaridis K., Tzartos S.J. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020;11:212. doi: 10.3389/fimmu.2020.00212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Mao Z.F., Yang L.X., Mo X.A., Qin C., Lai Y.R., He N.Y., et al. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci. 2011;121:121–129. doi: 10.3109/00207454.2010.539307. [DOI] [PubMed] [Google Scholar]
  • 100.Tzartos J.S., Zisimopoulou P., Rentzos M., Karandreas N., Zouvelou V., Evangelakou P., et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol. 2014;1:80–87. doi: 10.1002/acn3.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Rivner M.H., Liu S., Quarles B., Fleenor B., Shen C., Pan J., et al. Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients. Muscle Nerve. 2017;55:430–432. doi: 10.1002/mus.25438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Gomez A.M., Froemke R.C., Burden S.J. Synaptic plasticity and cognitive function are disrupted in the absence of Lrp4. Elife. 2014;3 doi: 10.7554/eLife.04287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Pohlkamp T., Durakoglugil M., Lane-Donovan C., Xian X., Johnson E.B., Hammer R.E., et al. Lrp4 domains differentially regulate limb/brain development and synaptic plasticity. PLoS ONE. 2015;10 doi: 10.1371/journal.pone.0116701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Sun X.D., Li L., Liu F., Huang Z.H., Bean J.C., Jiao H.F., et al. Lrp4 in astrocytes modulates glutamatergic transmission. Nat Neurosci. 2016;19:1010–1018. doi: 10.1038/nn.4326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Zhang H., Chen W., Tan Z., Zhang L., Dong Z., Cui W., et al. A role of low-density lipoprotein receptor-related protein 4 (LRP4) in astrocytic Aβ clearance. J Neurosci. 2020;40:5347–5361. doi: 10.1523/JNEUROSCI.0250-20.2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Mitoma H., Yoneda M., Saitow F., Suzuki H., Matsunaga A., Ikawa M., et al. Presynaptic dysfunction caused by cerebrospinal fluid from a patient with the ataxic form of Hashimoto's encephalopathy. Neurology and Clinical Neuroscience. 2014;2:104–108. doi: 10.1111/ncn3.105. [DOI] [Google Scholar]
  • 107.Mitoma H., Adhikari K., Aeschlimann D., Chattopadhyay P., Hadjivassiliou M., Hampe C.S., et al. Consensus paper: neuroimmune mechanisms of cerebellar ataxias. Cerebellum. 2016;15:213–232. doi: 10.1007/s12311-015-0664-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Burbelo P.D., Iadarola M.J., Keller J.M., Warner B.M. Autoantibodies targeting intracellular and extracellular proteins in autoimmunity. Front Immunol. 2021;12 doi: 10.3389/fimmu.2021.548469. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary data 1
mmc1.doc (118.5KB, doc)
Supplementary data 2
mmc2.doc (88.5KB, doc)
Supplementary data 3
mmc3.doc (130.5KB, doc)
Supplementary data 4
mmc4.doc (30KB, doc)

Articles from Journal of Clinical & Translational Endocrinology are provided here courtesy of Elsevier

RESOURCES